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Abbreviation 
AD     Alzheimer’s disease 
ADP   adenosine diphosphate 
ALS   amyotrophic lateral sclerosis 
AmpR   ampicillin resistance 
AOX   alternative oxidase 
ATP   adenosine triphosphate 
bp           base pair 
BSA         bovine serum albumin  
CLB         cell lysis buffer  
CMT         Charcot-Marie-Tooth disease  
CPEO        chronic progressive external ophthalmoplegia  
DAPI         4',6-diamidino-2-phenylindole 
DDM       N-Dodecyl-2-D-Maltoside 
DMEM      Dulbecco’s modified Eagle's medium 
DMSO        dimethyl sulfoxide 
EDTA         ethylenediaminetetraacetic acid  
EGFP         enhanced green fluorescent protein 
EGTA         ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
FADH2        flavin adenine dinucleotide  
FBS          fetal bovine serum  
GAPDH       glyceraldehyde-3-phosphate dehydrogenase 
HD           Huntington's disease  
HEK293T     human embryonic kidney cells 293T 
HEPES       4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
iPSC         induced pluripotent stem cells  
IRES         internal ribosome entry site 
LB           lysogeny broth 
LHON        Leber’s hereditary optic neuropathy  
Midiprep   midipreparation  
Miniprep  minipreparation 
mtDNA       mitochondrial DNA 
NADH       nicotinamide adenine dinucleotide 
Ndi1         NADH dehydrogenase   
nPG         n-propyl gallate 
OXPHOS     oxidative phosphorylation 
PBS         phosphate-buffer saline 
PCR         polymerase chain reaction  
PD          Parkinson's disease  
PDL         poly-D-lysine hydrobromide 
PES         polyethersulfone 
PFA         paraformaldehyde 
PLL         poly-L-Lysine 
PMSF       phenylmethanesulfonyl fluoride  
PVDF       polyvinylidene difluoride 
Q           ubiquinone/ubiquinol  
RIPA        radioimmunoprecipitation assay buffer 
ROS         reactive oxygen species  
RT          room temperature  
SCAs        Spinocerebellar ataxias  
SDHA       succinate dehydrogenase complex flavoprotein subunit A 
SDS-PAGE    sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHAM       salicyclhydroxamic acid  
TBS         Tris-buffered saline 
TLB         tissue lysis buffer  
TMPD       N,N,N’,N’-tetramethyl-p-phenylenediamine  
TR          rhodamine 
U2OS        human bone osteosarcoma epithelial cell 
WB         western blotting  
WRE        woodchuck hepatitis virus Post-transcriptional Regulatory Element 
WT         wild type 
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1. Introduction: 
In most eukaryotic organisms, there is a double-membrane-bound organelle called 
mitochondrion, which acts as a powerhouse of the cell (Henze and Martin, 2003). The 
mitochondrion is responsible for the aerobic respiration in eukaryotic cells, converting 
carbohydrates and oxygen into adenosine triphosphate (ATP) by the process of 
oxidative phosphorylation (Cooper, 2000). According to a popular hypothesis about 
the origin of mitochondrion, the mitochondrion arose from an aerobic prokaryote, 
which was then engulfed by an anaerobic nucleated cell as endosymbiosis (Marten 
and Mentel, 2010). Therefore, the nucleated cell acquired a more efficient way of 
producing energy with the help of mitochondria and evolved to modern eukaryotes. 
This origin may explain why mitochondria have their own genome. Although most 
genes encoding mitochondrial proteins have been transferred into the nucleus during 
evolution, the genes that remain in the mitochondria are essential for the transcription 
and translation of certain inner-membrane protein subunits (Alberts et al., 2015).    
Mitochondria are known to play an important role in aging and many cellular 
processes, such as energy production, glucose metabolism and cell signaling. If 
mitochondria are unable to function properly in the cell, they may impact the health of 
the organism. Some neurodegenerative diseases including Alzheimer's disease (AD), 
Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's 
disease (HD) are considered to involve mitochondrial dysfunction and blockade of 
mitochondrial respiratory chain (Lin and Beal, 2006). Unfortunately, most of the 
mitochondrial disorders lack effective treatments.  
To seek a potential therapy for mitochondrial diseases, an alternative oxidase (AOX) 
originated from Ciona intestinalis, has been applied to counteract the defects of 
mitochondrial respiratory chain in mice (El-Khoury., 2013). Additionally, previous 
studies on plants (Maxwell et al., 1999), drosophila (Liu et al., 2007) and human 
cultured cells (Dassa et al., 2009) have strongly supported that the expression of AOX 
provides a bypath of blocked respiratory chain, reducing the reactive oxygen species 
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(ROS) and ameliorating cell damages. These inspiring results indicate that AOX may 
be a promising tool for curing mitochondrial diseases. Therefore, an engineered 
mouse model has been created to express the Ciona intestinalis AOX ubiquitously in 
the whole animal so that the function of AOX can be studied in the mammalian 
system comprehensively (Szibor et al., 2017).  
1.1. The structure and function of mitochondria 
1.1.1 Structure 
The complex structure of mitochondrion is formed by two specialized membranes, 
segregating the intact organelle into two compartments: the intermembrane space and 
the internal matrix. These membranes are critical for defining distinct functions of 
mitochondria due to different transmembrane proteins located on each membrane.  
The outer mitochondrial membrane is similar to the eukaryotic plasma membrane. It 
encloses the entire organelle and allows free diffusion of all the molecules that weigh 
6000 daltons or less through certain membrane proteins called porins, making the 
composition of small molecules and pH uniform between the intermembrane space 
and the cytosol (Alberts et al, 2015).  
The inner membrane is more selective to the molecules that pass through it. Since the 
membrane has a large amount of cardiolipin, most of hydrophilic molecules are 
efficiently isolated outside the membrane, especially the ions (Alberts et al, 2015). 
This characteristic provides an ideal environment for the enzymes in the matrix to 
perform specific metabolic reactions, as only essential molecules can be imported into 
the matrix by certain transport proteins. Besides the specific transport proteins, the 
inner membrane also harbors a variety of functional enzymes, including the ATP 
synthase and respiratory enzyme complexes. The inner membrane folds on itself to 
form massive convoluted structures called cristae, which largely increases the surface 
area of the inner membrane, enabling more functional protein complexes to settle 
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down.  
The internal compartment enclosed by the inner membrane is the matrix, where the 
mitochondrial genome and ribosome as well as a variety of metabolic enzymes are 
located. The matrix is the most important place for the citric acid cycle of oxidative 
metabolism. Pyruvate and fatty acids, derived from sugars and fats respectively, can 
be converted to acetyl CoA in the matrix and further oxidized for fuels through the 
citric acid cycle. Therefore, the matrix contains the majority of enzymes catalyzing 
the oxidation of fatty acids and carbohydrates. 
1.1.2 Function 
1.1.2.1 Oxidative phosphorylation  
The most prominent contribution of mitochondria is the energy they produces for the 
cell. The major energy is produced in the form of ATP, through a series of redox 
reactions during aerobic respiration, or specifically oxidative phosphorylation. There 
are four complexes involved in this process, namely NADH dehydrogenase, succinate 
dehydrogenase, cytochrome c reductase, and cytochrome c oxidase, widely known as 
complex I, II, III, and IV, respectively (Berg et al., 2002; Alberts et al., 2015). These 
complexes are embedded in the inner mitochondrial membrane and serve as electron 
transporters. Altogether, they form a respiratory chain as electron carriers and pump 
protons across the inner membrane of mitochondria, generating an electrochemical 
gradient between mitochondrial matrix and crista space. This electrochemical gradient 
drives both ATP synthesis and active transport of specific molecules across the 
mitochondrial membrane. 
The sophisticated redox reactions in the respiratory chain can be divided into three 
stages (see Fig 1). In the first stage, complex I transfers two electrons from the 
reduced form of nicotinamide adenine dinucleotide (NADH) to an electron-carrier 
called ubiquinone (Q), pumping four protons from the matrix to the intermembrane 
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space. Ubiquinone also takes electrons from the reduced form of flavin adenine 
dinucleotide (FADH2) through complex II. However, complex II pumps no proton 
across the inner mitochondrial membrane. The second stage happens in the complex 
III, where the electrons carried by the reduced form of Q (ubiquinol) are transferred to 
cytochrome c, and four protons are pumped outside the inner membrane. Therefore, 
the ubiquinol returns to its original state. The reduced cytochrome c generated by 
complex III is finally oxidized by complex IV in the last stage, along with the 
reduction of oxygen to two molecules of water. Thus, four more protons are 
transferred through the inner membrane (Berg et al., 2002).  
After the three stages of redox reactions, the ATP synthase, also called complex V, 
carries out phosphorylation reactions to produce energy. Based on the chemiosmotic 
coupling hypothesis (Mitchell P, 1966), the proton gradient generated by the electron 
transport chain promotes the translocation of protons of higher concentration in the 
intermembrane space, back to the matrix through the ATP synthase. This flux releases 
a large amount of free energy that is then used by the ATP synthase to drive 
phosphorylation of adenosine diphosphate (ADP), storing the free energy in a 
chemical form so that it can be utilized in other biochemical reactions. 
 
Fig 1. The electron transportation pathway in the mitochondrial respiratory chain 
The main components consisting of the mitochondrial respiratory chain are shown. In the 
respiratory chain, electrons (orange thin arrows) are transferred from NADH and FADH2, passed 
by Complex I, Complex II, Complex III as well as electron carriers ubiquinone (Q) and 
cytochrome c (Cyt c), finally accepted by the O2 to produce H2O through Complex IV. Complex I, 
III and IV pump out protons (green arrows) from mitochondrial matrix to intermembrane space 
during this process.   
1.1.2.2 Glucose metabolism 
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Mitochondrion is not only a powerhouse for the cell, it also plays an important role in 
glucose metabolism. Although glycolysis, the first step of glucose metabolism, starts 
in the cytoplasm, the metabolic products of glycolysis are highly involved in 
biochemical reactions of mitochondria. As mentioned in the end of 1.1.1, pyruvate is 
decarboxylated in the mitochondrial matrix to produce acetyl CoA, which is the 
common metabolite of catabolisms of carbohydrate, lipid and protein. Acetyl CoA is 
also the primary substrate of the citric acid cycle (Krebs and Johnson, 1937). As the 
final pathway of these essential catabolisms, the citric acid cycle is responsible for 
oxidizing nutrients absorbed by organisms into carbon dioxide and water. During this 
process, the citric acid cycle generates many intermediate metabolites, which also 
participate in other metabolisms such as lipid and amino acid synthesis. Moreover, the 
citric acid cycle saves a great amount of energy in the form of NADH, coupled with 
the electron transport chain and ATP synthesis (Voet et al, 2013).  
1.1.2.3 Other functions 
In addition to the indispensable contribution in the energy production and glucose 
metabolism, mitochondria are involved in a number of critical cellular metabolisms. 
For example: the calcium homeostasis, is controlled by both the endoplasmic 
reticulum and the mitochondrial calcium uniporter (Kirichok et al, 2004). The 
thermogenic function in brown adipose tissue is also related to an uncoupling protein 
UCP1 embedded in mammalian mitochondrial inner membrane (Mozo et al, 2005). 
Furthermore, mitochondria even affect various key events of cell cycle and apoptosis 
(Green and Reed, 1998).  
Interestingly, the morphology of mitochondria is not invariable. Studies about 
mitochondrial dynamics have implied that the morphology of mitochondria plays a 
role in cell signaling, tissue development and neuronal functions (McBride et al, 
2006).  
According to the important functions mentioned above, it is significant to learn about 
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mitochondria. This small organelle contains big potential to maintain human health, 
cure diseases, and delay senescence. 
1.2.  Mitochondrial dysfunction and respiratory chain 
disorders 
Given all the benefits provided, the mitochondrion holds a fundamental position in the 
human body. On the other hand, defects of mitochondrial function may lead to severe 
health problems. As a result of dysfunction of mitochondrial respiratory chain, a 
variety of symptoms can arise in different tissues, including muscle weakness, heart 
failure, dementia, optic or auditory disorders, developmental delay and respiratory 
complications (Federico et al., 2012). Based on the cause of mitochondrial 
dysfunction, most of mitochondrial diseases can be divided into two categories: either 
of primary or secondary origin. A primary mitochondrial disease results from 
mutations in the mitochondrial genome or nuclear gene that encodes mitochondrial 
proteins; while a secondary mitochondrial disease results from both of the damaged 
genes and external environmental or pharmacologic factors (Filler et al., 2014). 
Commonly, mitochondrial dysfunction has been treated as a rare disease. However, 
due to a lack of accurate diagnostic methods for this dysfunction, the prevalence of 
mitochondrial diseases is likely to be underestimated. By 2008, the estimated rate of 
having mitochondrial diseases was about 9.2 in 100,000 people, and a further 16.5 in 
100,000 people were at risk for developing this sort of disease (Schaefer et al., 2008).  
1.2.1. Primary mitochondrial disease 
The mitochondrion has its own DNA (mtDNA), which encodes the mitochondrial 
proteins involved in the respiratory chain. Defects or mutations of mtDNA may cause 
numerous mitochondrial disorders, especially in the oxidative phosphorylation 
(OXPHOS) system. Myopathies such as chronic progressive external 
ophthalmoplegia (CPEO) are the most commonly manifested symptom for mtDNA 
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defects of OXPHOS in clinical (Leonard and Schapira, 2000). Similarly, 
encephalomyopathies and Leber’s hereditary optic neuropathy (LHON) are also 
associated with defective mitochondrial genes. Even if mtDNA defects can affect 
every tissue in the body, muscle and brain are often more severely affected than other 
tissues because of their high dependence on the energy provided by OXPHOS. More 
complications can be developed in multiple systems later on. Due to the maternal 
inheritance of mitochondria, these diseases always show a maternal inheritance in the 
offspring. 
Except for the small amount of mitochondrial genes, most of gene products that 
compose the proteins of mitochondrial respiratory chain are still expressed and 
transported from the nuclear DNA (DiMauro and Schon, 2003). Mutations in these 
genes will lead to mitochondrial diseases as well. For example, mutated genes of 
nuclear-encoded Complex II subunits can result in Leigh’s syndrome, which is a 
neurologic disorder arising from childhood. Moreover, a NADH-binding-site encoded 
gene mutation in the nuclear genome can even cause myoclonic epilepsy psychomotor 
delay and leukodystrophy in children. (Leonard and Schapira, 2000) 
1.2.2. Secondary mitochondrial disease 
Not all mitochondrial diseases are caused by the genes that maintain the structure and 
function of mitochondrial respiratory chain. Proteins that are responsible for the 
transportation or assembly of mitochondrial proteins may also result in disorders 
within OXPHOS system. Deficiencies of non-OXPHOS mitochondrial proteins that 
lead to respiratory chain dysfunction, belong to a second type of mitochondrial 
disease. Compared with primary mitochondrial diseases, the secondary mitochondrial 
diseases are more complicated in clinical manifestations. Many neurodegenerative 
diseases are involved in this group, including Friedreich’s ataxia, Hereditary spastic 
paraparesis, Epilepsy, Alzheimer’s disease, Wilson’s disease, Huntington’s disease 
and Parkinson’s disease (Leonard and Schapira, 2000). The secondary mitochondrial 
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diseases are generally inherited by autosomal inheritance or emerge sporadically 
instead of maternal inheritance. 
Owing to the heterogeneity of molecular backgrounds, the underlying mechanisms of 
mitochondrial dysfunction remain unclear. Therefore, neither curative treatment nor 
proper diagnostic method for mitochondrial diseases has been established (Khan et al., 
2015). Most of the available therapies aim at alleviating the symptoms derived from 
these diseases (Suomalainen, 2011). However, various mouse models have been 
widely applied to the mitochondrial research, conferring promises to expand the 
knowledge about mtDNA maintenance and develop new therapies for mitochondrial 
diseases (Tyynismaa and Suomalainen, 2009).  
1.3.  AFG3L2 gene knock down cell may serve as an in vitro 
disease model 
Spinocerebellar ataxias (SCAs) are autosomal dominantly inherited ataxias that 
belong to neurodegenerative disorders. Patients with these diseases show significant 
neuronal cell degeneration in the cerebellum and have weak control of muscles 
(Paulson,H.L, 2009). The genetic causes of many SCAs have been discovered so far, 
one example is the spinocerebellar ataxias 28 (SCA28). SCA28 is a slowly 
progressive ataxia resulting from cerebellar damage at onset from early adulthood. 
Based on the sequence analysis, mutations in the AFG3L2 gene were the only known 
genetic defects that lead to SCA28 (Di Bella et al., 2010; Brussino, 2013). 
1.3.1. AFG3L2 gene 
AFG3L2 gene encodes a subunit of the m-AAA metalloprotease in the mitochondrial 
inner membrane and is closely related to paraplegin (Atorino et al., 2003). The 
m-AAA metalloprotease is involved in mitochondrial protein quality control process, 
including turnover of mistranslated mitochondrial protein and respiratory chain 
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complexes assembly (Juhola et al., 2000). Therefore, mutated AFG3L2 gene encoding 
deficient m-AAA metalloprotease can lead to proteolytic defects, dysfunction of 
mitochondrial respiratory chain and excessive ROS production. Since AFG3L2 gene 
is highly expressed in human cerebellar Purkinje cell and crucial for axonal 
development (Maltecca et al., 2008), haploinsufficiency of this gene can cause 
neurodegeneration in the cerebellum (Maltecca et al., 2009). 
1.3.2. Mitochondrial dynamics and quality control  
As the most important powerhouse of eukaryotic cells, mitochondria have developed 
many strategies to maintain their functions through mitochondrial quality control. 
Under the regulation of various quality control proteins, slightly damaged 
mitochondria can be repaired by fusion with healthy mitochondria and mixing the 
content, while severe damaged mitochondria are removed by mitophagy or can induce 
cell apoptosis (Tatsuta and Langer, 2008). Mitochondrial dynamics involves the 
fusion and fission processes of mitochondrial membrane and reflects mitochondrial 
morphology of the cell. It is a vital mechanism for mitochondrial quality control 
regulated by dynamin-related GTPase machineries, including MFN1, MFN2, OPA1 
and DRP1 in mammals (Detmer and Chan, 2007).  
Mitofusins MFN1 and MFN2, located in mitochondrial outer membrane, regulate the 
mitochondrial membrane fusion reaction (Chen et al., 2003). The inner membrane 
protein Optic atrophy 1 (OPA1), which has several splice variants, also regulates 
mitochondrial membrane fusion (Lee et al., 2004; Song et al., 2007) and cristae 
structure remodeling (Frezza et al., 2006). On the contrary, DRP1 controls the 
mitochondrial fission progress (McBride et al., 2006). Both of the mitochondrial 
dynamic processes are essential for cells. Mitochondrial fusion is an efficient way to 
replace mutant mtDNA and compensate damaged components in dysfunctional 
mitochondria, while mitochondrial fission lead to segregation and autophagy of 
irreparable mitochondria. Disruption of these regulatory proteins for mitochondrial 
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dynamics is associated with cellular dysfunction and predisposition to diseases. For 
example, knockout of MFN1 and MFN2 genes in mouse embryonic stem cells leads to 
lethality (Chen et al., 2003), and mutated MFN2 is correlated with 
Charcot-Marie-Tooth disease (CMT) (Züchner et al., 2004). Patients carrying OPA1 
mutations commonly have multi-system neurological disorders (Yu-Wai-Man et al., 
2010), such as the dominant optic atrophy notably (Delettre et al., 2000; Alexander et 
al., 2000). The aberrant interaction between DRP1, amyloid beta and phosphorylated 
tau has been associated with Alzheimer’s disease (Manczak and Reddy., 2012).  
1.3.3. Loss of AFG3L2 gene causes OPA1 protein cleavage and 
mitochondrial fragmentation 
OPA1 is a dynamin-related GTPase that controls mitochondrial fusion by proteolytic 
cleavage. In human, 8 mRNA variants were found by alternative splicing during 
OPA1 gene transcription (Delettre et al., 2001). These different mRNA splice forms 
produce two types of protein isoforms: one long isoform (L-OPA1) and several short 
isoforms (S-OPA1). Both OPA1 isoforms work corporately to support mitochondrial 
fusion (Song et al., 2007). Remarkably, the destabilization of L-OPA1 results in OPA1 
processing and loss of protein activity, thus causing mitochondrial fragmentation.  
The m-AAA metalloprotease regulates the OPA1 processing. Loss of AFG3L2 gene 
can significantly decrease the stability of L-OPA1 in human cells and stimulate the 
cleavage of OPA1 by OMA1, which is also a metallopeptidase similar to m-AAA 
metalloprotease (Ehses et al., 2009). Higher cell percentage of fragmented 
mitochondria was observed in dominant-negative AFG3L2 variant human cells than 
in normal cells (Ishihara et al., 2006). Additionally, respiratory dysfunction and 
mitochondrial Ca
2+
 uptake are also consequences of AFG3L2 deficiency (Maltecca et 
al., 2012). Neuroscience studies have indicated that dysfunction of AFG3L2 gene is 
predisposed to neurodegenerative disorders such as SCA28 (Di Bella et al., 2010) and 
spastic ataxia-neuropathy syndrome (Pierson et al., 2011). According to these facts, 
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we believe that knocking down of AFG3L2 gene in human cells may lead to an in 
vitro disease model for imitating neurodegenerative diseases. 
1.4.  Alternative pathway for compensating respiratory 
chain defects  
Apart from the classical respiratory chain complexes, scientists have also found 
alternative enzymes that are involved in mitochondrial electrons transportation. These 
enzymes exist in many organisms, such as fungi, microbes, plants and certain animal 
phyla. The NADH dehydrogenase (Ndi1) makes Saccharomyces cerevisiae insensitive 
to rotenone by replacing complex I functionally (Matus-Ortega et al., 2015). The 
alternative oxidase (AOX) confers cyanide-resistance to lower animals such as Ciona 
intestinalis and Crassostrea gigas (McDonald et al., 2004). These enzymes can 
provide an alternative pathway for electrons to pass through the blocked respiratory 
chain, thus protecting the organism under unfavorable conditions. Although 
alternative enzymes are not found in arthropods and mammalians, they show no 
detrimental phenotype when expressed in drosophila (Fernandez-Ayala et al., 2009) 
and mouse models (El‐Khoury et al., 2014). Therefore, we see the alternative enzyme 
as a new therapy for mitochondrial diseases from the aspect of rescuing the 
mitochondrial respiratory chain. 
1.4.1. Function and application of alternative oxidase 
The alternative oxidase (AOX) is a membrane-bound enzyme that transfers electrons 
from ubiquinone pool to convert the oxygen into water, bypassing the cytochrome c 
pathway of the respiratory chain (see Fig 2). This enzyme was first found in the study 
of thermogenic bloom in aroids (Meeuse, 1975), AOX helps flowers produce heat to 
spread scent so as to attract insects for pollination. As a terminal oxidase of many 
plants, AOX also enables the mitochondria to tolerate certain toxins such as cyanide. 
In the presence of cyanide, cytochrome c oxidase fails to pass electrons to oxygen 
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through the mitochondrial respiratory chain, leading to excessive ROS and failure of 
ATP production. However, AOX makes the mitochondria insensitive to cyanide as it 
can transport electrons from substrates to oxygen by itself. Interestingly, the activity 
of AOX is usually maintained at low level unless the traditional respiratory chain is 
inhibited or blocked, which can stimulate the AOX activity (Rogov et al., 2014). The 
alternative pathway provided by AOX seems like a compensational oxidative 
mechanism under stress conditions such as oxidative stress, temperature changes, 
drought, nutrients shortage and so on, increasing the metabolic flexibility of cells. 
Besides plants, AOX was also found in yeast, fungi, protist, algae (McIntosh, 1994), 
and lower invertebrate animals such as Ciona Intestinalis (McDonald et al., 2004).    
However, AOX gene no longer exists in vertebrates, probably due to gene loss event 
during the evolution (McDonald et al., 2009). AOX protein has been applied in 
several animal models for studying its expression and function in mitochondria. 
Drosophila engineered to express AOX ubiquitously, showed antimycin and cyanide 
resistance of mitochondria, along with rescued function of oxidative phosphorylation 
in mutated cytochrome chain (Fernandez-Ayala et al., 2009). Studies have further 
supported the therapeutic function of AOX by the alleviation of defective phenotypes 
in the drosophila which had cytochrome oxidase deficiency (Kemppainen et al., 2014) 
and increased lifespan of the drosophila that produced human beta-amyloid in neurons 
(El-Khoury et al., 2016). Similar results were observed in mouse models as well. The 
expression of AOX in the transgenic mice reduced the ROS production and 
maintained the electron flow in the blocked mitochondrial respiratory chain 
(El-Khoury et al., 2013). Better still, AOX affects no normal physiology of the 
transgenic mice (Szibor et al., 2017). Moreover, scientists also applied AOX to human 
cells to study the mitochondrial respiratory chain defects and found its therapeutic 
potential on mitochondrial diseases (Hakkaart et al., 2006; Dassa et al., 2009). 
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Fig 2. AOX provides an alternative way for electrons flow in the respiratory chain 
In the presence of AOX (yellow triangle), the electrons transferred from ubiquinone (Q) can 
bypass the traditional respiratory chain and directly reduce the oxygen to produce water. However, 
AOX helps nothing in proton pumping across the mitochondria membrane and generates no 
energy.  
1.4.2. Regulation of AOX activity 
The activity of AOX is widely regulated by both genetic and epigenetic factors. 
Different transcription factors control the AOX expression in different species. 
Arabidopsis thaliana has a variety of transcription factors that affect AOX expression, 
including ABI4 (Giraud et al., 2009), NAC factors (Clercq et al., 2013) AtWRKY40 
and AtWRKY63 (Aken et al., 2013). While aod-2, aod-4, aod-5, aod-6, aod-7 genes 
regulate the AOX expression in fungi (Rogov et al., 2014). In addition to genetic 
factors, substrates involved in the respiratory chain can also regulate AOX activity at 
posttranslational level. Pyruvate is a common substrate that activates the AOX 
function. Whereas in some isoenzymes of sacred lotus, the AOX activity is insensitive 
to pyruvate but can be enhanced by succinate (Grant et al., 2009). In fungi and yeast, 
purine mono- or diphophates activate AOX in the presence of substrates 
(Sierra-Campos et al., 2009). 
As mentioned in 1.4.1, the regulation of AOX activity also depends on stress 
conditions. Disruption of the mitochondrial respiratory metabolism is one of the 
critical reasons to induce the expression of AOX in mitochondria. A sharp increase of 
AOX expression was observed in tobacco when antimycin A inhibited the cytochrome 
pathway (Vanlerberghe et al., 1994), leading to significant respiration in the 
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alternative pathway. Analogous results were also found when citrate, acetate, H2O2, or 
cysteine was introduced to the tobacco cell, meaning that AOX can be upregulated by 
multiple metabolites and stresses (Vanlerberghe et al., 1996). Further study regarding 
Arabidopsis suggested that the expression level of AOX also varied from tissues and 
developmental stages based on different genotypes from the same gene family 
(Clifton et al., 2006). 
On the other hand, AOX has its specific inhibitors. N-propyl gallate (nPG) and 
salicyclhydroxamic acid (SHAM) are two common inhibitors that efficiently inhibited 
the cyanide-resistant oxygen consumption in Plasmodium falciparum (Murphy et al., 
1997). These inhibitors shut down the alternative electron transportation pathway 
provided by AOX, forcing the electrons in mitochondrial membrane to pass the 
cytochrome c pathway merely. Because of this function, SHAM and nPG are widely 
used to eliminate the impact of AOX on mitochondrial respiration. 
1.5.  Viral vector as a tool to express AOX gene in 
mammalian cells 
On account that AOX protein is absent in mammals, the recombinant DNA 
technology can be applied to express the AOX gene of Ciona intestinalis in 
mammalian cells or tissues. An engineered double-stranded circular DNA, known as 
plasmid, is the basic component for accomplishing this goal. Plasmids are commonly 
found in bacteria such as E. coli. These small circular DNA carry different genes than 
the chromosome and can replicate independently, which makes them ideal vectors for 
gene cloning. Usually, recombinant plasmids have gene markers that express 
antibiotic resistance, allowing for screening of positive clones subsequently. Plasmids 
can transfer the gene of interest directly into the target cells by transfection, or 
proliferate the gene in competent bacteria by transformation. The gene delivered by 
plasmid transfection can only be expressed transiently in host cells, because the 
genome of host will not integrate the plasmid gene. However, Ti plasmid of 
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Agrobacterium tumefaciens is an exception, which can insert the foreign gene from 
T-DNA region of plasmid into plant genome (Stachel aandNester, 1986). 
Due to the limitation of plasmid transfection, a more stable vector has been 
established in many research fields, that is the virus. There are a variety of viral 
vectors capable for delivering exogenous gene into host cells, some can even integrate 
the carried gene into the genome of the host. Each of these viruses has different 
advantages and drawbacks. But they generally own predominant qualities such as less 
cytotoxic, genetically stable, and highly flexible for various cell types. Four types of 
most commonly used viral vectors are listed in Table 1. 
Compared with all the characteristics of other viral vectors, the lentivirus is more 
advantageous for stably expressing AOX in the human cells that divide slowly. 
Efficient transfer ability and sustained gene expression of lentiviral vectors have been 
observed in rodent tissue, HEK293T cells (Naldini et al., 1996), U2OS cells 
(Stegmeier et al., 2005), and human fibroblasts (Mali et al., 2008). To improve the 
safety of lentivirus packaging, separated plasmids that contain different viral genes 
were generated as the 3
rd
 generation lentivirus packaging system (Dull,T et al., 1998). 
In this system, two packaging viral vectors and one envelop vector are co-transfected 
along with the recombinant plasmid into cells, so that intact viruses can be integrated 
in the cells and released into the cell culture medium. By this method, transgenic 
lentiviruses are produced but with loss of the ability to proliferate uncontrollably. 
 Adenovirus Adeno-Associated 
virus 
Retrovirus Lentivirus 
Virus gene size 36kb 8.5kb 7-11kb 8.5kb 
Insert gene size 8kb 5kb 8kb 9kb 
Gene type dsDNA ssDNA ssRNA ssRNA 
Gene integration No Yes (specific site) Yes Yes 
Efficiency High High Medium Medium 
Target cell Dividing and 
non-dividing 
Dividing and 
non-dividing 
Dividing Dividing and 
non-dividing 
Disadvantage Strong immune 
response 
Require helper virus 
to replicate, hard to 
Host cell 
mutagenesis 
Host cell 
mutagenesis 
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guarantee purity potential potential 
Table 1. Comparison of four common viral vectors (adapted from Thermo fisher scientific) 
The table lists the virus gene size, insert gene capacity, gene type, gene integration, infection 
efficiency, target cell and disadvantages of four common viral vectors. One can choose the most 
suitable vector depending on the purpose of experiment and essential features of each vectors.  
1.6.  Aim of study 
Although being underestimated by many people, mitochondrial diseases are among 
the most important diseases that significantly threaten human health. Especially the 
dysfunction of mitochondria in the brain, since brain is the most energy dependent 
organ, leads to various neurodegenerative diseases which lack of efficient treatments. 
Despite huge challenges, scientists are actively exploring potential therapies to 
conquer these stubborn diseases.  
As introduced previously, AOX has the beneficial characteristic to compensate the 
defects in the mitochondrial respiratory chain by providing an alternative electron 
pathway and alleviating the excessive oxygen stress. Hence we see AOX as a 
promising candidate to cure mitochondrial diseases. Considering that AOX is absent 
in human, we established a transgenic mouse model to express Ciona AOX gene 
ubiquitously in the animal for our study (Szibor et al., 2017). However, by comparing 
the expression level of AOX protein in different tissues of the transgenic mouse 
model, we found that AOX was expressed surprisingly lower in the brain than heart or 
any other tissues (see Fig 3). 
To explore how this happened and define the real function of AOX in the brain, both 
at tissue level and cell level, we started our study on this transgenic mouse model 
from two aspects. On one hand, we aimed at confirming the preliminary results of 
AOX expression in the mouse brain with more samples and different tissue extraction 
methods. In addition, we were also interested in the expression level of AOX in the 
isolated neuro-glia cells. On the other hand, we aimed at constructing a recombinant 
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viral vector to induce the expression of AOX in wild type mice and human cell lines, 
further investigating the AOX function under disease conditions. For example, we 
built an in vitro disease model that mimicked a type of neurodegenerative disease 
related to mitochondrial dysfunction, and the viral vector could be applied to this 
disease model to test whether AOX can alleviate any symptoms caused by 
mitochondrial defects.   
 
Fig 3. AOX expression in different mouse organs  
Western blots of 20μg total tissue protein extracted from hemizygous AOX
Rosa26
 transgenic mice 
and wild type mice were probed with AOX, tubulin and SDHA antibodies separately. Blots show 
relatively low expression of AOX protein in cerebrum and cerebellum compared with other tissues 
(Szibor et al., 2017). 
2. Material and method 
2.1. Materials 
2.1.1. Mouse model 
The AOX
Rosa26
 transgenic mouse model was generated from the mouse embryonic 
stem cell (Srinivas et al., 2001), in which the AOX gene from Ciona intestinalis was 
knocked into the Rosa26 gene locus (Friedrich and Soriano, 1991; Szibor et al., 2017). 
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The AOX transgene was expressed all over the body of the transgenic mouse driven 
by CAG promoter (Hitoshi et al., 1991). And the AOX
Rosa26
 transgenic mouse line was 
maintained by backcrossing to strain C57Bl/6J and mating between littermate siblings. 
The genotype of each mouse was checked consistently by PCR. 
2.1.2. Chemicals and solution 
2.1.2.1 Western blotting buffers 
12% Separating gel (5ml)  
The gel was made by mixing 1.6ml of distilled water, 2ml of 30%Acrylamide/Bis 
solution (BIO-RAD #1610156), 1.3ml of 1.5M Tris-HCL (pH 8.8), 25µl of 20% SDS, 
50µl of 10% APS and 2µl of TEMED (BIO-RAD #1610800) until the gel was 
polymerized. 
Stacking gel (2ml)  
The gel was made by mixing 1.4ml of distilled water, 330µl of 30%Acrylamide/Bis 
solution (BIO-RAD #1610156), 250 µl of 1.0M Tris-HCL (pH 6.8), 10µl of 20% SDS, 
20µl of 10% APS and 2µl of TEMED (BIO-RAD #1610800) until the gel was 
polymerized. 
SDS-PAGE running buffer 
1x running buffer was prepared by diluting 10x stock (purchased from Institute of 
Biotechnology Media Kitchen) 1 in 10 with distilled water. The 10x stock contains 3% 
Tris, 14.4% glycine and 1% SDS in Mili-Q water. 
5x Laemmli buffer 
The buffer was made by dissolving 0.312M Tris-HCL (pH 6.8), 10% SDS, 50% 
glycerol, 25% β-Mercaptoethanol and 0.05% bromophenol blue in distilled water. 
Semidry transfer buffer 
The buffer purchased from Institute of Biotechnology Media Kitchen contains 0.3% 
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Tris, 1.44% glycine and 20% methanol in Mili-Q water. 
TBST (Tris buffered saline/0.1% Tween 20) buffer  
The buffer was diluted from 10x TBS pH=7.4 (purchased from Institute of 
Biotechnology Media Kitchen) with 0.1% of Tween 20. 10x TBS contains 3% Tris, 8% 
NaCl, 0.2% KCl in Mili-Q water. 
Blocking buffer 
The buffer was prepared by dissolving 1.5% (w/v) non-fat milk powder in TBST. 
Western Blot stripping solution 
The solution was made by mixing 100mM β-Mercaptoethanol, 2% SDS, 62.5mM 
Tris-HCL (pH 6.8) in distilled water. 
Primary antibody solution 
AOX [customized rabbit antibody, 21st Century Biochemicals (Fernandez-Ayala et al., 
2009)], dilution ratio was 1:50000 or 1:10000 
α-tubulin (Cell Signaling Technology #3873), dilution ratio was 1:2000 
GAPDH (Cell Signaling Technology #5174), dilution ratio was 1:1000 
SDHA (Abcam #ab14715), dilution ratio was 1:10000 
AFG3L2 (Proteintech #14631-1-AP), dilution ratio was 1:5000 
OPA1 (BD Biosciences # 612606), dilution ratio was 1:10000 
The antibodies were diluted in the TBST solution containing 5% bovine serum 
albumin (protease free BSA, Jackson ImmunoResearch #001-000-162). 
Secondary antibody solution 
Anti-rabbit (Jackson ImmunoResearch #111-035-144), dilution ratio was 1:20000 
Anti-mouse (Jackson ImmunoResearch #115-035-146), dilution ratio was 1:10000 
The antibodies were diluted in TBST. 
Luminol chemiluminescent solution 
The luminol chemiluminescent substrates were mixed from 20x LumiGLO Reagent 
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and 20x Peroxide (Cell Signaling Technology) and diluted in water according to the 
manufacturer's recommendations. 
2.1.2.2 Protein extraction buffers 
1xPBS (Phosphate-buffer saline) buffer 
The buffer purchased from Institute of Biotechnology Media Kitchen contains 0.8% 
NaCl, 0.02% KCl, 0.14% Na2HPO4 x 2H2O, 0.02% KH2PO4 in Mili-Q water. 
10xPBS buffer 
The buffer purchased from Institute of Biotechnology Media Kitchen contains 8% 
NaCl, 0.2% KCl, 1.4% Na2HPO4 x 2H2O, 0.2% KH2PO4 in Mili-Q water. 
Tissue lysis buffer 
The buffer contains 50mM Tris-HCL (pH 7.5), 150mM NaCl, 1mM EDTA, 1% Triton, 
2.5mM PMSF and Pierce protease inhibitor tablet (Thermo Fisher Scientific) 
dissolved in Mili-Q water.  
Cell lysis buffer 
The buffer was made by dissolving 1%DDM (N-Dodecyl-2-D-Maltoside), 1mM 
PMSF (Phenylmethanesulfonyl fluoride solution) and one tablet of Pierce protease 
inhibitor (Thermo Fisher Scientific) in 10ml 1xPBS. 
RIPA buffer (Sigma #R0278) 
The buffer contains 150mM NaCl, 1%IGEPAL® CA-630, 0.5% sodium deoxycholate, 
0.1% SDS, and 50 mM Tris, pH= 8.0. 
2.1.2.3 Cell culture solutions 
FBS (Fetal Bovine Serum) solution 
The stock solution (Thermo Fisher Scientific #10270106) was inactivated in 56
o
C 
water bath for 30min and aliquoted in -20
o
C freezer before use. 
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DMEM complete medium 
The medium was made by adding 10% FBS, 1% GlutaMAX™ Supplement (Thermo 
Fisher Scientific #35050038) and 1% Pen/Strep (Lonza #DE17-602E) in high glucose 
DMEM medium (Lonza #BE12-614F). 
DMEM galactose medium (no glucose) 
The medium was made by adding 1% Pen/strep (Lonza #DE17-602E), 1% 100mM 
sodium pyruvate solution (Sigma #S8636), 10mM Galactose, 10% FBS in DMEM no 
glucose medium (Thermo Fisher Scientific #11966025, with L-glutamine). 
Neurobasal A complete medium 
The medium was made by adding 1% Pen/strep (Lonza #DE17-602E), 1% 
GlutaMAX™ Supplement (Thermo Fisher Scientific #35050038) and 10% B-27™ 
Supplement (Thermo Fisher Scientific #17504044) in CTS™ Neurobasal™-A 
Medium (Thermo Fisher Scientific #A1371001) 
0.0025% PDL (Poly-D-lysine) 
The solution was made by dissolving PDL powder (Sigma #P7280) in distilled water. 
0.01%PLL (Poly-L-Lysine) 
The solution was made by dissolving PLL powder (Sigma #P2636) in distilled water. 
0.25% Trypsin (no EDTA) solution 
The solution was prepared fresh by diluting Trypsin Solution (2.5%) 10X (Sigma 
#59427C) in PBS. 
0.05% Trypsin-EDTA solution 
The solution was diluted from Trypsin-EDTA (0.5%) Solution 10X (Thermo Fisher 
Scientific #15400054) in PBS. 
Antimycin A solution 
The solution was made by dissolving Antimycin A from Streptomyces sp. (Sigma 
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#A8674) in pure ethanol. 
2.1.2.4 Transfection solutions 
5x KCM buffer 
The buffer contains 500mM KCL, 150mM CaCl2 and 250mM MgCl2 in sterile water. 
LB medium 
The medium purchased from Institute of Biotechnology Media Kitchen contains 1% 
tryptone, 0.5% yeast extract and 0.5% NaCl in Mili-Q water. 
Lipofectamine 2000 transfection reagent (Invitrogen #11668019) 
Lipofectamine RNAiMAX transfection reagent (Invitrogen #13778030) 
Opti-MEM reduced serum medium (Invitrogen #31985062) 
siRNA  
Stealth RNAi™ siRNA Negative Control (Invitrogen #12935300) 
Human AFG3L2 stealth siRNA (Invitrogen #HSS116886) 
2.1.2.5 Oxygraph solutions and immunostaining buffers 
Mitochondrial respiration medium (MiR05) 
The buffer was made of 0.5mM EGTA, 3mM MgCl2, 60mM lactobionic acid (Sigma 
#153516, pH adjusted to 7.0 with 5M KOH), 20mM taurine (Sigma #T0625), 10mM 
KH2PO4, 20 mM HEPES/KOH, 110mM sucrose and 1mg/ml fatty-acid free BSA 
(Sigma #A7030), pH was adjusted to 7.2 at room temperature. 
Mitochondrial extraction buffer 
The buffer was made of 225mM sucrose, 75mM D-mannitol, 10mM Tris base, 1mM 
EGTA, and 1mg/ml fatty-acid free BSA in H2O, pH was adjusted to 7.4 with HCL. 
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Rotenone solution 
The solution was made by dissolving rotenone powder (Sigma #R8875) in pure 
ethanol. 
4% PFA buffer 
4% Paraformaldehyde powder (Sigma #158127) was dissolved in Mili-Q water by 
water bath and 10x PBS buffer was diluted into 1x PBS with the dissolved 
paraformaldehyde solution. Final pH was adjusted to 7.2 by pH meter. The buffer was 
filtered by a falcon cell strainer (Thermo Fisher Scientific #08-771-1). 
PBST buffer 
The buffer was made by adding 0.1% of Tween 20 into 1x PBS buffer. 
2.2. Methods and techniques 
2.2.1. Genotyping and gel electrophoresis 
DNA samples were extracted from ear punches or tail snips of the mice by 
AccuStart™ II Mouse Genotyping Kit according to manufacturer’s instructions. 
Genotypes were verified by PCR using AccuStart II GelTrack PCR SuperMix (2X) 
with primers AOX 317F (5’-GCGATGCAAGATGGAGGGTA-3’) and AOX 317R 
(5’-TGAATCCAACCGTGGTCTCG-3’), plus Rosa26_wt_gtF 
(5’-GACCTCCATCGCGCACTCCG-3’) and Rosa26_wt_gtR 
(5’-CTCCGAGGCGGATCACAAGC-3’). All the primers were ordered from Sigma. 
The PCR was performed in a thermal cycler with the final reaction volume of 25μl, 
including 1μl of extracted DNA sample, 0.16μM of each primer, 12.5μl of the 
AccuStart II GelTrack PCR SuperMix (2X). The PCR thermal cycling condition was 
set up as follows: initialization for 3min at 95
o
C, denaturation for 20s at 95
o
C, 
annealing for 30s at 56
o
C, extension for 40s at 72
o
C, repetition for 35 cycles, and final 
elongation for 8min at 72
o
C. PCR products were separated in a 1% agarose gel, at 
90V for 1h. 
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Fig 4. AOX gene location and primers design 
In the genome of the AOX
Rosa26
 transgenic mouse model, Ciona AOX gene (orange) is inserted 
into the Rosa26 gene sequence (blue). The sizes of PCR product amplified by AOX primers and 
Rosa26 primers are 317bp and 523bp, respectively. 
2.2.2. Protein extraction 
2.2.2.1. Protein extraction from the cell 
Cultured cells were washed with PBS and removed from the plate by a scraper or 1x 
trypsin solution (trypsinized the cell for 5min at 37
o
C). Cells were further centrifuged 
for 5min at 400xg to discard the supernatant, and cell pellets were resuspended in cell 
lysis buffer. After 30min of incubation on ice, the protein lysate was separated from 
the cell residue by centrifugation for 15min at 20000xg, 4
o
C.  
2.2.2.2. Protein extraction from the tissue 
200μl tissue lysis buffer was added for 20-30mg tissue and homogenized on ice with 
scissors and pestles. Tissue lysate was incubated on ice for 30min and centrifuged for 
5min at 14000xg, 4
o
C.  
2.2.2.3. Measurement of protein concentration  
Protein concentration was estimated by Bradford assay (Bradford, 1976) using diluted 
Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-rad #5000006) and a 
microplate reader (SpectraMax 190, Molecular Devices). 0, 1, 2, 4, 8 mg/ml of BSA 
were used to prepare the standard gradient. 
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2.2.3. Western blotting 
2.2.3.1. Customized gel protocol 
Protein samples were diluted to the same concentration, mixed with 5x laemmli buffer 
and loaded into the SDS-PAGE self-made gel for electrophoresis. The self-made gel 
was made of 2 layers, including a 12% polyacrylamide gel and a stack gel. The 
electrophoresis was carried out in a SDS-PAGE running chamber (Bio-rad) for 1.5h at 
100V. Separated proteins were transferred from the gel to a PROTRAN nitrocellulose 
membrane in the Owl™ HEP-1 Series Semidry Electroblotting Systems (Thermo 
Fisher Scientific) for 1h at 0.04A, at room temperature. The western blot membrane 
was then blocked with blocking buffer (1.5% milk in TBST), and incubated with 
primary antibody solution overnight at 4
o
C. Next day, the membrane was washed in 
TBST (10min for each wash, repeated 3 times) and probed by peroxidase-conjugated 
secondary antibody for 1h at room temperature. After the same washing steps as 
before, the membrane was soaked in the luminol chemiluminescent solution for 3 min 
and detected by a ChemiDoc XRS Imaging System. 
2.2.3.2. Commercialized gel protocol 
In this protocol, the self-made gel was replaced by a 4–20% 
Mini-PROTEAN® TGX™ Precast Protein Gel (Bio-rad #4561093). A 
Trans-Blot® Turbo™ Mini PVDF Transfer Pack (Bio-rad #1704156) was used for the 
semidry transfer blotting in a Trans-Blot® Turbo™ Transfer System (Bio-rad). The 1 
mini gel TGX programme was selected for the transfer system according to 
manufacturer’s instructions. The PVDF membrane was further treated and detected as 
the same as in 2.2.3.1. 
2.2.3.3. Stripping 
Stripping steps were implemented when more than one primary antibodies needed to 
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be blotted. The stripping buffer was prewarmed to 56
o
C before stripping. Membranes 
were stripped for 30min at room temperature and washed twice in TBST buffer, each 
wash lasted for 15min. Antibody was added to the membrane after 30min of blocking 
with blocking buffer. 
2.2.4. Cell culture 
2.2.4.1. Cell line maintenance 
Primary neuro-glia cell 
To separate neuro-glia cells from the mouse brain, the cortex was collected from the 
cervical dislocated mice and cut into pieces with scissors in PBS. The brain pieces 
were trypsinized for 5min at 37
o
C and further triturated in DMEM complete medium. 
The triturated brain cells were resuspended in DMEM before plating onto 6 well cell 
culture plate, which was coated by 0.0025%PDL in advance. The cells were first 
cultured in DMEM complete medium for 1 day and then changed to neurobasal A 
complete medium with all the cell debris cleaned out. The incubation condition was 
37
o
C with 5% CO2. 
HEK293T cell 
The cell line was cultured in DMEM complete medium. Medium was changed every 
3 days. And cells were subcultured when cell confluence reached 100%. 4x10
6
/ml of 
cells were frozen in FBS solution with 10% DMSO (Sigma #D2650) for preservation.   
U2OS 
The cell line was cultured in DMEM complete medium. Medium was changed every 
3 days. And cells were subcultured when cell confluence reached 100%. One full 
confluent 10cm
2
 plate of cells were frozen in FBS solution with 10% DMSO (Sigma 
#D2650) for preservation. 
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2.2.4.2. Antimycin A treatment 
The neuro-glia cells were cultured in DMEM complete medium for 1 day, and in 
neurobasal A complete medium for 2 days before the treatment. Cells were washed 
with PBS once and cultured in DMEM galactose medium (no glucose) for antimycin 
A treatment. Different amount of antimycin A solution was added to each well of 6 
well cell culture plate and cell viability was recorded under the inverted microscope 
(Leica DMi1) with a camera after 24h of treatment. 
2.2.4.3. Plate coating 
The plates should be coated before primary neuro-glia cell culture and HEK293T cell 
transfection. For neuro-glia cell culture, 1ml of 0.0025%PDL solution was used to 
coat each well of 6 well cell culture plate for 5min, and the solution was washed away 
by sterile water for 3 times. 1ml of DMEM complete medium was added to each well 
when the plate was completely dry. The plate was incubated at 37
o
C before use. For 
HEK293T cell transfection, 10ml of 0.01%PLL solution was used to coat 10 cm
2 
plate 
for 5min, followed by the same washing and drying steps as PDL, and 37
o
C DMEM 
complete medium was added to the plate before introducing cells. 
2.2.5. Mitochondrial respiration 
2.2.5.1. Mitochondrial extraction 
Mice were sacrificed by cervical dislocation for mitochondrial extraction. Tissues 
collected from the mice were chopped into pieces of 2mm
3
 in ice-cold PBS and 
further into 1mm
3
 in 3ml of ice-cold mitochondrial extraction buffer by scissors. 
Tissue pieces were homogenized in mitochondrial extraction buffer by stroking 5-6 
times with a pestle in a glass-teflon homogenizer on ice. The homogenate was 
transferred to a 15ml falcon tube and centrifuged at 1300xg for 5min at 4
o
C. The 
supernatant of the homogenate was collected and re-centrifuged at 17000xg for 15min 
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at 4
o
C. Mitochondrial pellet was resuspended in ice-cold MiR05 buffer (protease 
inhibitor added) before the respirometry. The concentration of mitochondria was 
measured using Bradford assay (Bradford, 1976).   
2.2.5.2. Mitochondrial respirometry 
The mitochondrial oxygen consumption was measured by a high-resolution 
respirometry: oxygraph-2k (OROBOROS Instruments, Austria). Respiratory 
chambers of the oxygraph were washed thoroughly 3 times with 70% ethanol and 3 
times with Mili-Q water. A calibration of the polarographic oxygen sensor was 
performed before the experiment following the manufacturer’s protocols (Pesta and 
Gnaiger, 2012). 50 or 100μg of mitochondria were added to each respiratory chamber 
which contained 2.2ml of MiR05 buffer. After 5min of equilibrium, following 
substrates and inhibitors were added to each chamber in order: (1) 5mM of sodium 
pyruvate, 5mM of sodium glutamate and 5mM of sodium malate, (2) 2mM of ADP, (3) 
150nM of rotenone, (4) 17mM of sodium succinate, (5) 22.5ng/ml of antimycin A, (6) 
250μM of n-propyl gallate (nPG), (7) 0.5mM of 
N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD) plus 2mM of sodium 
L-ascorbate, (8) 50mM of sodium azide. The oxygen flux in each respiratory chamber 
was recorded by DatLab software simultaneously. The flux values were normalized 
according to the amount of mitochondria and analyzed with Microsoft Excel software.  
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Fig 5. Respirometry process 
(A) The process of respirometry. Red chemicals represent the inhibitors of specific complexes or 
enzyme. Green chemicals represent the substrates of those complexes. Pyruvate, sodium glutamate 
and sodium malate are abbreviated as P, G, M. (B) A representative oxygen consumption graph of 
oxygraph-2k, which shows the adding order of specific chemicals after the mitochondria have 
been added into the respiratory chamber, as well as how the oxygen concentration (blue bar, value 
on the left y-axis) and oxygen slope (red bar, value on the right y-axis) change during the whole 
process.  
2.2.6. Construction of AOX lentiviral vector 
2.2.6.1. Plasmid construction 
A pCDH-IRES-EGFP plasmid ordered from Systems biosciences was used as the 
backbone for our target plasmid. To insert Ciona AOX gene into the plasmid, the 
restriction enzymes EcoRI and NotI were used for digestion. 5μl plasmid DNA 
(plasmid concentration was 1-2μg/μl) was incubated with 10U of each enzyme in 50μl 
reaction system with FastDigest buffer (Thermo Fisher Scientific #B64) for 1h at 
37
o
C. After the gel electrophoresis of the digested plasmid, the backbone DNA was 
collected under UV light and extracted by a NucleoSpin Gel and PCR clean-up kit 
(Macherey-Nagel #740609). 11μl transgene and 5μl plasmid backbone were rejoined 
by 1μl T4 DNA ligase (Thermo Fisher Scientific #EL0011) in 20μl reaction system 
with ligase buffer for 2h at 16
o
C.  
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Fig 6. AOX plasmid construct 
The recombinant AOX plasmid of 10,045 bp contains the replication origin (Ori), the antibiotic 
marker of ampicillin (AmpR), the synthetic promoter (pCAG), the Ciona AOX gene, the internal 
ribosome entry site (IRES), the enhanced green fluorescent protein gene (EGFP), the Woodchuck 
hepatitis virus Post-transcriptional Regulatory Element (WRE) and the restriction sites EcoRI and 
NotI. 
2.2.6.2. Transformation 
5-50μg recombinant plasmid and 10μl 5X KCM buffer were added to 50μl chemically 
competent E. coli in 100μl reaction system. The mixture was incubated first on ice for 
20min and then at room temperature (RT) for 10min, after which 1ml of LB medium 
was added to it and altogether incubated for 1h at 37
o
C, 750 rpm. The transformed E. 
coli were spread on a LB agar plate with ampicillin and incubated at 37
o
C overnight. 
2.2.6.3. Amplification and purification of plasmid DNA 
Four random single colonies were picked from the LB agar plate and inoculated in 
3ml LB medium with ampicillin (50μg/ml) separately. The bacteria were incubated at 
37
o
C overnight at 220rpm. 
2ml of the LB culture was used for a minipreparation (miniprep) of plasmid DNA on 
the next day. The miniprep was accomplished with a NucleoSpin Plasmid Kit 
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(Macherey-Nagel #740588), according to manufacturer’s instructions. The purified 
DNA was digested with restriction enzymes EcoRI and NotI and separated on a 1% 
agarose gel. Correct plasmid was verified by the size of insert gene. 
Plasmid of the right size was further amplified by midipreparation (midiprep) using a 
NucleoBond Xtra Midi kit (Macherey-Nagel #740410) according to manufacturer’s 
instructions. 
2.2.6.4. Viral vector production 
5×10
6
 HEK293T cells (Passage<20) were seeded in a 10 cm
2
 PLL coated plate with 
10ml DMEM complete medium. Cells were split 1:8 to 3 plates if they reached 90% 
confluency, and the supernatant was collected for ultracentrifugation to concentrate 
the virus. Cell confluency of each plate should be 70% before transfection.  
In a 500μl transfection system, 7μg of transfer plasmid and 3.5μg of each packaging 
plasmid, including pRRE, pRSV and pMD2.G, was pre-mixed with 250μl of 150mM 
NaCl, while 36μl of jetPEI transfection reagent (Polyplus #101-10N) was pre-mixed 
with 250μl of 150mM NaCl. After 5min of incubation at RT, two parts of solution 
were combined together and mixed gently. The DNA-jetPEI complex was dropwise 
added to HEK293T cells in the 10cm
2
 plate after 20min of incubation at RT. The 
transfected cells were incubated at 37
o
C. 4h later, the cell culture medium was 
changed with 10ml of fresh DMEM complete medium. 
The supernatant containing virus was collected and filtered with a 0.45μm PES filter 
into 50ml falcon tube after 48-72h of cell culture. The virus could be used fresh or 
concentrated with an ultracentrifuge at 22000rpm for 2h at 4
o
C. Concentrated virus 
pellet was dissolved in 100μl PBS overnight at 4oC and aliquoted by 14μl per 1.5ml 
Eppendorf tube. Aliquoted virus concentrate was frozen in liquid N2 and stored in 
-80
o
C. 
The complete process of AOX viral vector production was shown in Fig 7. 
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Fig 7. Process of AOX viral vector production and infection 
The pCDH-AOX-IRES-EGFP recombinant plasmid was first transfected into HEK293T cells, 
together with three lentivirus packaging vectors. Then lentiviral particles was integrated and 
proliferated in the transfected cells. At last the viral particles were collected and concentrated from 
the cell culture medium and further infected U2OS cells. 
2.2.6.5. Viral vector infection 
2×10
5
 U2OS cells were seeded in each well of 6 well cell culture plate before the day 
of infection. 14μl of concentrated viral vector and 2μl of polybrene (10mg/ml) were 
added to medium of cultured U2OS cells (50% confluent). Cells were incubated for 
30min at 37
o
C and spun for 30min at 2500rpm afterwards. Cell culture medium was 
refreshed after 4 hours. 3 days later, the infection efficiency could be verified with 
fluorescence microscope. 
2.2.7.  Immunostaining 
2.2.7.1. Antibody immunostaining 
U2OS cells were split on the cover slips of the 6 well cell culture plate and cultured in 
DMEM medium. When confluency reached 50%-70%, cells were washed with PBS 
and fixed in 4% cold PFA buffer for 15min. Fixed cells were further washed with PBS 
and permeabilized with 99% cold Methanol for 5min. Permeabilized cells were 
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washed again with PBS and blocked with 5% BSA-PBST buffer for 1h at RT. Primary 
antibody was added onto the cover slips for 1h of incubation at RT. Cover slips were 
washed 3 times and subsequently incubated in diluted secondary antibody for 1h at 
RT in the dark. After 3 more washes, the cover slips were mounted to glass slides with 
Vectashield mounting medium and kept at +4
o
C. Used antibodies are listed below. All 
the antibodies were diluted in 5% BSA-PBST: 
ATP5a (mouse polyclonal) diluted by 1:500 
AOX (rabbit polyclonal) diluted by 1:400 
Alexa 594 (anti-mouse) diluted by 1:1000 
Alexa 568 (anti-rabbit) diluted by 1:1000 
2.2.7.2. Nucleic acid staining 
1mg/ml of DAPI (4',6-diamidino-2-phenylindole) fluorescence dye was diluted 
1:10000 in PBST. Cover slips were incubated in diluted DAPI for 15min in the dark at 
RT and washed 3 times before mounting. 
2.2.7.3. Imaging 
All the cover slips were imaged by the fluorescence microscope Imager-M2 (Carl 
Zeiss) with a high resolution camera (AxioCam HRC), according to manufacturer’s 
instructions. The optimized objective was 40x oil. The contrast reflectors of 38GFP 
(green), 45TR (red) and 49DAPI (blue) were used. Images were processed with Zen 
software using same settings. Mitochondrial dynamics was quantified with Image 
J-win64 software.    
2.2.8. Construction of in vitro disease model and AOX rescue test 
2.2.8.1. AOX infection on U2OS cell model 
On day 1, AOX infection was carried out as described in 2.2.6.5. Cell culture medium 
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was refreshed on day 2. Infected and uninfected U2OS cells were subcultured 1:3 in a 
6 well cell culture plate on day 3.   
2.2.8.2. AFG3L2 siRNA double transfection 
On day 4, the cell density should be about 50% 7.5μg of AFG3L2 siRNA or 
scrambled siRNA was pre-mixed with 250μl of Opti-MEM. And 4μl of Lipofectamine 
RNAiMAX was pre-mixed with 250μl of Opti-MEM. Two parts of solution was 
combined and mixed gently. After 10min of incubation at RT, 500μl of the mixture 
was added to the cell culture medium of U2OS cells (WT and AOX infected) 
On day 5, siRNA transfected cells were subcultured 1:2 if cell confluency reached 100% 
and the medium was refreshed. The same process of siRNA transfection was repeated 
on day 6.  
2.2.8.3. Identification of protein expression and mitochondrial fragmentation  
On day 7, cell culture medium was refreshed. Cultured U2OS cells were split for 
immunostaining and western blotting on day 8. For immunostaining, U2OS cells were 
fixed on day 9 and stained on day 10 according to the protocol 2.2.7. Cover slips were 
imaged as 2.2.7.3. 
For western blotting, U2OS cells were lysed with cell lysis buffer and frozen in -20
o
C 
on day 9, followed by protein extraction and western blotting on next day according 
to the protocol 2.2.3. The entire timing process is depicted as Fig 8. 
 
Fig 8. Process of AFG3L2 gene knock down and AOX rescue test on U2OS cell 
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On day 1 (D1), cultured U2OS cells were infected with AOX lentivirus. On day 4 (D4) and day 6 
(D6), infected cells were double-transfected with Afg3l2 siRNA. On day 9, treated cells were 
collected and divided into two groups. One group of cells was lysed for western blotting (wb), 
while the other group of cells was fixed for immunostaining.  
2.2.9. Statistical analysis 
Quantification analysis and calculation of mitochondrial respirometry were performed 
with Microsoft Excel software. Significance was calculated by student’s t-test with 
GraphPad Prism software. Notable significance was marked as ** (P<0.005). 
3. Results 
The Rosa26 gene, located on chromosome 6, is an advantageous site for genetic 
modification in mice. Gene targeting at this site is relatively efficient, and the 
expression is ubiquitous in many types of cells (Irion et al., 2007). Our transgenic 
mouse model was created by the insertion of a single Ciona AOX gene into the 
Rosa26 locus of the mouse embryonic stem cell. After more than 7 generations of 
backcrossing to strain C57Bl/6J, the transgenic mouse line was maintained stably. The 
AOX expression of transgenic mice was detected both at mRNA level and protein 
level by northern blotting and western blotting in all tissues. Uneven expression of 
AOX was seen in different tissues at both levels, with especially low expression in the 
brain (Szibor et al., 2017).  
3.1. Low expression of AOX in the brain of 1-month-old 
hemizygous AOX
Rosa26
 transgenic mouse  
To verify the preliminary results of low expression level of AOX protein in the brain, 
repeated western blotting was carried out. Protein samples were extracted from cortex, 
cerebellum and heart tissue. Genotypes of the protein samples were confirmed by 
PCR. The western blots in Fig 9 show that AOX protein was expressed much lower in 
cortex and cerebellum than heart of the 1-month-old hemizygous AOX
Rosa26
 transgenic
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mouse. However, SDHA protein seems to be an improper loading control for mice 
tissue because of unspecific bands (*) shown in cerebellum and cortex.  
 
Fig 9. AOX expression in the cortex, cerebellum and heart of 1-month-old hemizygous 
AOX
Rosa26
 transgenic
 
mice and wild-type mice 
(A) Representative PCR results of hemizygous AOX
Rosa26
 transgenic
 
mouse and littermate 
wild-type (WT) control. DNA samples were extracted from the mouse tail snips. The gene ruler is 
marked as M, and mice genotypes are marked as WT (-/-), AOX (+/-). (B) Western blots of AOX 
and SDHA proteins from brain and heart. Each sample contains 20μg total protein extracted 
respectively from cortex (ctx), cerebellum (cb) and heart (hrt) of 1-month-old hemizygous 
AOX
Rosa26
 transgenic
 
mouse and WT control. Blots were probed with antibody AOX 1:50000 and 
SDHA as loading control. * represents unspecific bands. The result has been confirmed in 
triplicate. 
3.2. AOX expression in the primary neuro-glia cells of new 
born mice 
Neurons are the most important cells in the brain. They undertake the main functions 
of nerve system, transmitting electrical and chemical signals between each other 
through synapses, thus regulating metabolism and activity of the whole organism. 
Neurons are unable to live alone. They need to be supported and protected by glia 
cells, which help optimize the brain function. Knowing how AOX is expressed in the 
isolated neuro-glia cells would be meaningful to imply whether it is functional in the 
brain (Skatchkov et al., 2014; Peng et al., 2014).  
Although the expression level of AOX is very low in cortex and cerebellum, this 
protein can be expressed as high as heart in the primary neuro-glia cells, which were 
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isolated from the brains of newborn mice (Fig 10). This finding interestingly 
contradicts the result from Fig 9. To investigate whether the process of neuro-glia cell 
culture had any effects on the expression of AOX, cultured cells were collected at 
different time points (1d, 2d, 3d and 4d), and extracted cell proteins were loaded in 
the same gel to compare the content of AOX protein during the time course of cell 
culture. By comparing the intensity of target bands between four samples on the 
western blotting membrane, we could see there was no significant change of AOX 
expression during the cell culture period.  
 
Fig 10. AOX expression in the primary neuro-glia cell of new born hemizygous AOX
Rosa26
 
transgenic
 
mice and wild-type mice 
Western blots show AOX and α-tubulin proteins of the primary cultured neuro-glia cells from 
hemizygous AOX
Rosa26
 transgenic
 
mice and WT mice born in 3 days. For each sample, 20μg total 
protein were extracted from the cells, probed with antibody AOX 1:10000 and α-tubulin as 
loading control. Protein extracted from heart tissue of 1-month-old hemizygous AOX
Rosa26
 
transgenic
 
mice was loaded as positive control. Cells were collected at different time points during 
primary cell culture, from 1 day (1d) to 4 days (4d). Genotypes of the cells are marked as AOX 
heterozygote (+/-) or wild-type (-/-). The result has been confirmed in triplicate. 
3.3. Antimycin A resistance of primary neuro-glia cells 
expressing AOX 
Antimycin A is a common toxin for studying cellular responses to the inhibited 
mitochondrial respiratory chain. This toxin can effectively block the complex III of 
mitochondrial respiratory chain (Kim et al., 1999) and increase the reactive oxygen 
species (ROS) in the cells (Maxwell et al., 1999). Excessive antimycin A can even 
lead to cell death. However, ROS induced by antimycin A decreases significantly in 
 38 
the presence of AOX, and the damaged respiratory activity is also alleviated in human 
cells that contain AOX (Matsukawa et al., 2009). To test the functionality of AOX 
protein in the primary neuro-glia cells, cells expressing AOX and WT cells were 
treated with antimycin A in DMEM galactose medium for 24h. After the treatment, 
two cell lines performed different cell viability as shown in Fig 11. Although 
antimycin A inhibited the cell proliferation comparing treated cells (c,d) with 
untreated cells (a,b), AOX cells grew better than WT cells under antimycin A 
treatment. WT cells shrank and detached from the plate while AOX cells remained 
normal morphology, indicating that WT cells suffered more stress than AOX cells due 
to the cytotoxicity of antimycin A. Therefore, AOX protein expressed in the 
neuro-glia cells was functional and could improve the cell resistance to antimycin A.  
 
 
Fig 11. Cell viability of primary neuro-glia cells after antimycin A treatment 
Primary neuro-glia cells were isolated from the brains of 3-day-old hemizygous AOX
Rosa26
 
transgenic
 
mice and WT mice. Cells were cultured in neurobasal A complete medium for 2 days, 
and transferred to DMEM galactose medium during antimycin A treatment. (a), (b) show the cell 
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viability of AOX cells and WT cells after 24h culture in DMEM galactose medium. (c), (d) show 
the cell viability of AOX and WT cells treated with 0.5μM antimycin A for 24h in the same 
medium. Representative dead cells are pointed out by red arrows. The results have been confirmed 
in triplicate. 
3.4. Buffer optimization for tissue protein extraction  
Given the different expression levels of AOX in the brain tissue and neuro-glia cells 
of transgenic mice, it is easy to associate the inconformity with the possibility that the 
buffer used for extracting the protein from mouse brain was less efficient compared 
with those for neuro-glia cells.  
To optimize the extraction buffer for AOX protein, three different solutions were 
tested, including cell lysis buffer (CLB), tissue lysis buffer (TLB) and 
radioimmunoprecipitation assay buffer (RIPA). Compared with other buffers shown in 
Fig 12, RIPA buffer demonstrated a slightly better efficiency for protein extraction 
from the mouse brain. The amount of AOX protein extracted by RIPA buffer was 
higher than that extracted by cell lysis buffer, which was used for the protein 
extraction of neuro-glia cells. Therefore, RIPA buffer was selected as the optimized 
extraction buffer for tissue in the subsequent experiments. Although extraction buffer 
changed, the expression level of AOX was still much lower in the brain than in the 
heart, inconsistent with the result of neuro-glia cells. 
 
Fig 12. AOX protein extracted from 1-month-old mouse brain by different buffers 
Western blots show 20μg total protein extracted from the brain of 1-month-old hemizygous 
AOX
Rosa26
 transgenic
 
mice and WT control, probed with antibody AOX 1:10000 and reprobed for 
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GAPDH after stripping as loading control. The same brain samples were extracted by cell lysis 
buffer (CLB), tissue lysis buffer (TLB) and RIPA buffer respectively. Protein from the heart of 
1-month-old hemizygous AOX
Rosa26
 transgenic
 
mice was used as positive control. Genotypes of the 
tissue are marked as AOX heterozygote (+/-) or wild-type (-/-).  
3.5. AOX expression in the brain of different ages of 
hemizygous AOX
Rosa26
 transgenic
 
mice 
Based on the previous findings, the difference of AOX protein level between brain 
tissue and neuro-glia cells is not due to the efficiency of protein extraction. Another 
possibility comes out, that the new born mice used for neuro-glia cell culture might 
have a higher expression level of AOX, than the 1-month-old mice used for tissue 
extraction in the brain. 
To verify this hypothesis and investigate the change of AOX protein in the brain, the 
hemizygous AOX
Rosa26
 transgenic
 
mice brains of four different ages (1 day, 1 week, 2 
week, 1 month) were tested and compared with each other. Interestingly, a significant 
decline of AOX protein level was observed in the brain of hemizygous AOX
Rosa26
 
transgenic
 
mice along with the increase of age (Fig 13). However, the loading control 
GAPDH shows uneven level among samples, causing difficulties to compare the 
amount of AOX protein.   
 
Fig 13. AOX expression in the brain of different ages of hemizygous AOX
Rosa26
 transgenic 
mice 
Western blots show 20μg total protein extracted from the brain of hemizygous AOX
Rosa26
 
transgenic
 
mice at different ages, probed with AOX antibody 1:10000 and reprobed for GAPDH 
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after stripping as loading control. Four ages of mice were selected as check point of AOX 
expression, including 1 day (1d), 1 week (1w), 2 week (2w) and 1 month (1m). Protein from the 
heart of 1-month-old hemizygous AOX
Rosa26
 transgenic
 
mice was used as positive control. 
Different samples from mice of the same age were loaded in parallel. 
3.6. Mitochondrial respiratory activity in the brain and liver 
of hemizygous AOX
Rosa26
 transgenic
 
mice 
To test the AOX function in the tissues of hemizygous AOX
Rosa26
 transgenic mice, the 
mitochondrial oxygen consumption rate was measured by oxygraph-2k and recorded 
by DatLab software. By using different inhibitors and substrates which inhibit or 
stimulate specific mitochondrial complexes, the respiratory activity of each part of the 
mitochondrial respiratory chain can be measured according to the oxygen 
consumption rate (see Fig 14).  
 
Fig 14. Representative mitochondrial oxygen consumption graph 
The change of mitochondrial oxygen consumption activity during 2.5h is shown. Selected values 
of oxygen slope are marked with numbers from (01) to (09). AOX respiratory activity is correlated 
with antimycin resistance and can be calculated as the value of [(06)-(07)]/μg protein 
(mitochondria) per chamber. Complex I activity is calculated as the value of [(03)-(04)]/μg protein 
(mitochondria). Complex II activity is calculated as the value of [(05)-(07)]/μg protein 
(mitochondria). Complex IV activity is calculated as the value of [(08)-(09)]/μg protein 
(mitochondria). 
Respiratory activities of three mitochondrial complexes and AOX protein were 
quantified separately. Respiratory activities of AOX in the brain and liver of different 
ages (3 day, 4 day, 1 week, 2 week, 4 week) were analyzed and compared side by side. 
As shown in Fig 15, the decline of AOX respiratory activity in the brain was 
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correlated with the age, this is also in consonance with the decline of AOX expression. 
Overall, the AOX respiratory activity in the liver was higher than that in the brain, 
despite of the fluctuation between different ages. However, the AOX respiratory 
activity might be underestimated in the liver, because mitochondrial respirometry of 
liver was always operated later than that of brain due to limited chambers of the 
oxygraph, meaning that the liver mitochondria were more exhausted than brain 
mitochondria at the time of measurement. This experiment was only carried out once 
on account of time limitation, but the result consisted with our expectation. 
 
Fig 15. Mitochondrial oxygen consumption activity of AOX in the brain and liver of 
hemizygous AOX
Rosa26
 transgenic
 
mice 
Mitochondrial oxygen consumption activity of AOX is shown along with mice age. The 
mitochondria were extracted from brain and liver of hemizygous AOX
Rosa26
 transgenic
 
mice. Mice 
ages include 3 days old (3d), 4 days old (4d), 1 week old (1w), 2 weeks old (2w) and 4 weeks old 
(4w). Brain and liver of 3-day-old wild-type mouse (wt) served as negative controls. 
In addition, respiratory activities of different mitochondrial complexes were analyzed 
and compared between the 3-day-old hemizygous AOX
Rosa26
 transgenic mice and WT 
control for both liver and brain, including Complex I, Complex II and Complex IV. As 
shown in Fig 16, the overall mitochondrial respiratory activity of AOX transgenic 
mice was higher than WT mice, and that of brain was higher than liver. Only complex 
II was an exception. However, more data should be collected to analyze the 
significance of difference before drawing a conclusion, because we only carried out 
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the experiment twice for AOX transgenic mice and once for WT mice due to limited 
materials.  
 
Fig 16. Oxygen respiratory activity of three mitochondrial complexes in the brain and liver 
of hemizygous AOX
Rosa26
 transgenic
 
mice 
Mitochondrial respiratory activities of Complex I, Complex II and Complex IV were measured by 
oxygraph-2k and graphed by GraphPad Prism. The mitochondria were extracted from brain and 
liver of 3-day-old hemizygous AOX
Rosa26
 transgenic
 
mice and WT mice at the same age. Error bars 
represent means±SD of two independent experiments. 
3.7. AOX viral vector construction and infection on U2OS 
cells 
In order to study the AOX function in the adult mouse brain and human cells, a 
lentiviral vector was constructed to induce the expression of AOX. The DNA plasmid 
that drove the expression of AOX was designed as Fig 6, with Ciona intestinalis AOX 
gene, the synthetic promoter (pCAG), the antibiotic marker of ampicillin (AmpR), the 
internal ribosome entry site (IRES), the enhanced green fluorescent protein gene 
(EGFP), the Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
(WRE) and the restriction sites EcoRI and NotI. The function of pCAG and WRE is to 
initiate and enhance the expression of AOX and EGFP gene. Sizes of both the insert 
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gene segment and plasmid backbone were verified by restriction digest and agarose 
electrophoresis (see Fig 17 A). The lentiviral vector was integrated by the AOX 
plasmid and three packaging plasmids, including pRRE, pRSV and pMD2.G. Integral 
lentivirus was further proliferated in HEK293T cells and concentrated by 
ultracentrifugation. Thus, the AOX gene could be delivered into the genome of U2OS 
cell through virus infection. The expression of AOX in these cells was confirmed by 
both western blotting (see Fig 17 B) and immunostaining (see Fig 18). The infection 
efficiency was about 30%. 
 
Fig 17. AOX plasmid digestion and AOX viral vector infection on U2OS cells 
(A) The constructed AOX plasmid digested by restriction enzymes EcoRI and NotI. DNA 
fragments are shown on the agarose gel. The genes and sizes of two DNA fragments are annotated 
beside the bands. (B) Western blots of 15μg total protein of the AOX lentivirus infected cells and 
WT cells. Blots were probed with antibody AOX 1:10000 and SDHA as loading control.   
Along with AOX, the EGFP gene was also expressed in the infected U2OS cells (see 
Fig 18 A). The purpose of inserting this gene into the plasmid is to track AOX by the 
enhanced green fluorescence protein. Interestingly, the expression levels of AOX and 
EGFP were not completely matched in the infected U2OS cells. In some cells, the 
green fluorescence from EGFP was invisible while the red fluorescence provided by 
AOX antibody was clear (see Fig 18 B). And the intensity of green fluorescence 
varied from cell to cell. This phenomenon indicated that the expression of EGFP was 
not be as stable as AOX in the infected U2OS cells, which might result from the 
regulation of IRES gene. 
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Fig 18. Representative immunostaining image of AOX infected U2OS cells 
The U2OS cells infected by AOX lentivirus were stained by AOX antibody in the mitochondrial 
membrane (red) and DAPI in the nucleus (blue). The enhanced green fluorescence protein (EGFP) 
was expressed in the infected cells (green). Scale bar 20μm. (A) Colocalization of EGFP and AOX 
in infected U2OS cell (white arrow). (B) Non-colocalization of EGFP and AOX in infected U2OS 
cell (yellow arrow) 
3.8. AFG3L2 gene knock down in vitro model and AOX 
lentivirus rescue 
We constructed the lentiviral vector in order to express the AOX gene in different cell 
lines or animal models, so that the function of AOX protein could be tested under 
certain conditions. Our interest is to investigate whether AOX has an effect on 
neurodegenerative diseases. Many neurodegenerative diseases are associated with 
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defects in mitochondrial respiration and mitochondrial dynamics. SCA28, caused by 
haploinsufficiency of AFG3L2, shows mitochondrial features such as respiratory 
deficiency (Di Bella et al., 2010), mitochondrial fragmentation (Karbowski and 
Neutzner, 2012) and ineffective mitochondrial Ca
2+ 
handling (Maltecca et al., 2015). 
Therefore, we built an in vitro disease model by knocking down the AFG3L2 gene in 
U2OS cells to mimic the neurodegenerative disease condition of SCA28. The 
AFG3L2 gene was transiently silenced in the U2OS cells by siRNA double 
transfection. By comparing the target characteristics of wild-type cells and AOX 
lentivirus infected cells, before and after the AFG3L2 siRNA transfection, we could 
evaluate the AOX potential of treating the disease.   
The infection of AOX lentivirus was accomplished three days before the AFG3L2 
gene knock down, ensuring that the U2OS cells expressed AOX and EGFP at the time 
of siRNA transfection. As a result of siRNA interference, the expression of AFG3L2 
protein decreased dramatically, both in the WT cells and AOX cells (see Fig 19). 
 
Fig 19. Protein expression of AFG3L2 and AOX in the U2OS cell disease model 
Western blots show different proteins in AOX lentivirus infected U2OS cells and wild-type control, 
3 days after double-transfection with AFG3L2 siRNA (Afg3l2) or scrambled siRNA (NC). (A) 
10μg of total protein samples probed with AFG3L2 antibody and reprobed for GAPDH. (B) 15μg 
of the same protein samples probed with AOX 1:10000 and reprobed for SDHA. Untransfected 
cells (UT) served as negative control. * represents unspecific bands. The results have been 
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confirmed in triplicate. 
OPA1 is one of the important proteins that regulates mitochondrial quality control. 
This protein has different isoforms in different organisms. Knocking down of 
AFG3L2 causes the destabilization of OPA1 protein, especially for the long isoform 
(L-OPA1) (Ishihara et al., 2006; Ehses et al., 2009). Therefore, western blots show 
different protein patterns of OPA1 after the AFG3L2 siRNA transfection (see Fig 20). 
The L-OPA1 degraded along with the silencing of AFG3L2 in U2OS cells, which was 
a sign of mitochondrial abnormality. The OPA1 patterns in AOX infected cells 
seemed the same as in WT cells, indicating that AOX protein failed to rescue the 
cleavage of L-OPA1 in the AFG3L2 defective U2OS cells. However, this result is not 
sufficient to demonstrate the relationship between AOX and OPA1. Many factors 
should be considered to judge the impact of AOX on these excessively manipulated 
cells.  
 
Fig 20. OPA1 expression in the U2OS cell disease model 
Western blots show 10μg total protein of WT and AOX lentivirus infected U2OS cells, after 
double-transfection with AFG3L2 siRNA or scrambled siRNA (NC). Blots were probed with 
OPA1 antibody and reprobed for SDHA as loading control. The OPA1 protein was present as two 
types of isoforms (L-OPA1 and S-OPA1) under normal condition, whereas the L-OPA1 
disappeared after knock down of AFG3L2 gene. Untransfected cells (UT) served as the negative 
cell control, while NC served as the negative transfection control. 
AFG3L2 is an important protease that regulates the process of OPA1 cleavage (Ehses 
et al., 2009). Loss of AFG3L2 can induce many cellular responses (Maltecca et al., 
2012; Kondadi et al., 2014), here we only focused on the changes of mitochondrial 
morphology in the cell. Therefore, we immunostained the U2OS cells after AFG3L2 
siRNA transfection and observed the mitochondria morphology in these cells. Mainly 
two types of mitochondrial structures were found: tubular and fragmented 
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mitochondria (see Fig 21 A). To quantify the difference of mitochondria morphology 
between AOX and WT cells, we scored the number of cells that contained tubular and 
fragmented mitochondria separately (see Fig 21 B). As expected, the cell number of 
tubular mitochondria decreased, while that of fragmented mitochondria increased 
significantly in the AFG3L2 knock down cells compared with the scrambled siRNA 
transfected cells. There was no significant difference of mitochondrial morphology 
between AOX and WT cells after scrambled siRNA transfection. Interestingly, AOX 
cells showed significantly less fragmented mitochondria than WT cells after the 
AFG3L2 siRNA transfection. This difference indicates that AOX might alleviate the 
disadvantages caused by loss of AFG3L2 and retain the normal mitochondrial 
morphology independently of OPA1 cleavage.  
 
Fig 21. Mitochondrial morphology in the U2OS cell disease model 
(A) Representative images of U2OS cells with tubular and fragmented mitochondria. 
Mitochondria were immunostained with ATP5a antibody. (B) Quantification of mitochondrial 
morphology in U2OS cells, transfected with scrambled siRNA or AFG3L2 siRNA, wild-type cells 
(WT) or AOX lentivirus infected cells. Tubular and fragmented mitochondria were scored and 
calculated as number of cells (%). Error bars represent means±SD of three independent 
experiments; ** represents P < 0.005 by Student’s t test. Sample sizes for scrambled siRNA are as 
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follows: n=96, n=129, n=116 cells counted for WT cells in each independent experiment 
respectively; n=55, n=13, n=25 cells counted for AOX cells. Sample sizes for AFG3L2 siRNA: n= 
122, n=174, n=150 cells counted for WT cells respectively; n=71, n=25, n=41 cells counted for 
AOX cells. 
4. Discussion 
4.1. AOX expression and activity in the transgenic mouse 
brain 
Low expression of AOX was observed in the cortex and cerebellum of adult 
transgenic mice. We confirmed this result by repeated western blotting with samples 
from different individuals and different concentrations of AOX antibody (1:50000 and 
1:10000). Protein sample from the heart was used as positive control because AOX 
was expressed at high level in the heart. However, it was still unknown whether the 
low expression level of AOX in the brain should be functional or in vain at this point. 
According to related studies on yeasts and fungi (Veiga et al., 2000; Nargang et al., 
2012), AOX shows barely activity under normal conditions but can increase its 
expression and become active when the mitochondrial respiratory chain is disturbed. 
The regulation of AOX is highly complex in different species and the activity of AOX 
is determined by various factors. The expression of AOX can be induced or inhibited 
in different conditions of organisms, tissues and cell types (Rogov et al., 2014). Thus, 
we isolated neuro-glia cells from the transgenic mouse brain to further study the 
expression and activity of AOX at cell level, as this cell type is especially important 
for neurodegenerative diseases. Surprisingly, the amount of AOX protein in the 
cultured neuro-glia cells was as high as that in heart tissue of 1-month-old transgenic 
mice. Besides, the antimycin A treatment test on the neuro-glia cells indicated that 
AOX protected the transgenic cells against the toxin and improved cell survival 
compared with WT cells. Although this result might not be convincing enough to 
identify specific function of AOX in neuro-glia cells, since cell apoptosis is a complex 
process affected by many other factors. At least the increased cell survival rate 
reflected the activity of AOX and assured that this protein is functional. Similar 
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results acquired from other cell lines have also given implications for the feature of 
AOX in neuro-glia cells (Hakkaart et al., 2006; Matsukawa et al., 2009), suggesting 
that antimycin A resistance can be considered as a reference indicator for the AOX 
activity. More quantifications should be done to verify the result as well as elaborating 
the functions of AOX, such as reduction of cellular ROS and oxygen consumption 
ability. However, the limited lifetime and rigid culture condition of primary neuro-glia 
cells restricted the application of many measurements.  
Based on the different expression level of AOX in the brain tissue and neuro-glia cells, 
several assumptions were proposed to explain this result. The first assumption was 
that, the expression of AOX could be induced during the cell culture process. AOX 
expression and activity are associated with the availability of nutrients and 
environmental conditions on the basis of posttranslational regulation. Neuro-glia cells 
cultured in vitro encounter high concentration of oxygen, abundant substrates and 
specific growth factors in the medium, which are highly different from the conditions 
in vivo. As a result, the expression of AOX might be up-regulated in the neuro-glia 
cells compared with that in the brain. In order to prove this assumption, we cultured 
the primary neuro-glia cells for four days, collecting cell samples every day, from the 
first day when cells were isolated, to the last day that cells could survive. However, no 
significant difference was found between the AOX contents of neuro-glia cells 
collected from each day, which meant the cell culture condition was not the reason of 
maintaining high expression level of AOX in the neuro-glia cells.  
The second assumption then arose, the protein extraction efficiency of AOX was not 
as high in the brain tissue as in the heart tissue and cells. This assumption was based 
on the special characteristics of AOX protein and brain. On one hand, AOX is an 
integral membrane protein which can be found in the mitochondrial membrane 
(Berthold and Stenmark, 2003). The structure of AOX contains a hydrophobic region 
tightly associated with the phospholipid head group, requiring detergent to separate 
this protein from the membrane (Berthold et al., 2000). Thus, the AOX protein is not 
as easily extractable as water-soluble proteins, and it is even harder to be solubilized 
and purified from animals than plants (Chaudhuri et al., 1995). On the other hand, 
brain is a special organ that contains large proportion of fat, which triggers more 
difficulties to the extraction of AOX protein. We compared the protein extracted in the 
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tissue lysis buffer with protein left in the cell pellet by western blotting. The level of 
AOX protein was surprisingly higher in the pellet than in the buffer (data not shown). 
Therefore, we tested three buffers to compare their extraction efficiency, including the 
cell lysis buffer used for the neuro-glia cells, the tissue lysis buffer used for the brain 
and heart tissues, and the RIPA buffer which is widely used for protein extraction. 
Although the RIPA buffer slightly increased the extraction efficiency of AOX protein, 
the expression level of AOX was still very low in the brain tissue compared with heart 
and neuro-glia cells. In addition, we also tested different extraction methods but none 
of them improved the amount of AOX protein extracted from the brain tissue. 
The third assumption was finally proved to be true, which suggested that the 
expression level of AOX in the brain was changed along with the age of transgenic 
mice. It has been reported that AOX expression can be various at different 
developmental stages in some organisms, such as Trypanosoma brucei (Walker et al., 
2005), Yarrowia lipolytica (Guerrero-Castillo et al., 2012) and Metarhizium 
anisopliae (Uribe et al., 2008). The mice used for neuro-glia cell isolation were 
newborns at the age of 1-3 days old, while the age of the mice used for brain tissue 
extraction was over 1 month. Thus we had good reason to suspect that the AOX 
expression in the brain was different between these mice. In fact, a decline of AOX 
expression was clearly detected in the brain from the 1-day-old pups to the 
1-month-old mice according to our result. On account that the antibody SDHA bound 
unspecific protein in the brain tissue, GAPDH was used to replace it as loading 
control. However, GAPDH also demonstrated limitations. The difference of GAPDH 
level between protein samples was probably resulted from the stripping process. 
Because GAPDH has a similar size to AOX, stripping is necessary for removing the 
AOX antibodies bound to the membrane and reprobing the samples with GAPDH 
antibodies. During the process of stripping, loss of protein was unavoidable, which 
might lead to reduced intensity of bands during chemiluminescent detection. To 
eliminate the effect of stripping, same samples should be ran in two gels in parallel, so 
that each membrane could be probed by different antibody at the same time. Moreover, 
although GAPDH is relatively stable across species as a housekeeping protein, the 
expression of this protein varies among different tissues (Barber et al., 2005; Ferguson 
et al., 2005). Hence, the loading control bands of heart and brain in Fig 13 were not 
even, suggesting that GAPDH was not an appropriate reference protein for both brain 
and heart tissue in this case. 
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The expression level of AOX in the transgenic mouse brain was associated with the 
AOX activity, which also decreased along with the age (from 4-day-old to 
4-week-old). Although there was a slight increase from 3 to 4 days old, more data 
should be collected to find the peak. Here, the AOX activity referred to the oxygen 
consumption ability of mitochondria or mitochondrial respiratory activity through the 
alternative pathway provided by AOX. This activity was measured by OROBOROS 
oxygraph-2k, a widely used respirometer in mitochondrial research (Aidet et al., 2013; 
Kim et al., 2015; Patel et al., 2015). Mitochondria isolated from the liver were used as 
the positive reference as AOX was highly expressed in this organ. Compared with 
liver, the AOX activity in the brain was always lower. Furthermore, the activities of 
other complexes in the mitochondrial respiratory chain were also measured for 
3-day-old mice, suggesting that the hemizygous AOX
Rosa26
 transgenic mice had higher 
complex activities than the WT mice, and the activities were higher in the brain than 
in the liver except for complex II. According to these findings, we suggest that AOX 
could improve the level of mitochondrial respiration. But the activity of AOX was 
lower in the brain compared with liver due to higher activities of other mitochondrial 
complexes in the brain. This is in accordance with the balancing characteristic of 
AOX whose activity can be induced by inhibition of main respiratory pathway while 
alternatively reduced in response to high respiration through the main pathway. 
However, lacking of repetitive experiments drew these results back before making 
solid conclusions. In addition, the complicated procedure of the mitochondrial 
isolation and limited chambers of oxygraph-2k respirometer caused mitochondria of 
the liver less healthy than those of the brain, leading to inaccuracy of the comparison 
between two tissues.   
To sum up, the most important result indicates that the expression and activity of 
AOX protein in the brain decreased substantially within one month. On the basis that 
preliminary results also showed a low mRNA level of AOX in the adult mouse brain 
(data not shown), the expression of AOX gene might have already been 
down-regulated since transcription. The regulatory mechanism in the brain was so 
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complicated that we could not determine which pathway was the leading factor. But at 
least these results provided a prediction that AOX protein might not show significant 
function in the brain of an adult hemizygous AOX
Rosa26 
transgenic mouse. Therefore, 
if we still insisted to study the function of AOX protein in the brain, we had to 
establish a biological tool to induce its expression. 
4.2. Lentiviral vector construction and AOX expression in 
virus infected cells 
Virus is a useful biological tool for introducing foreign protein in vivo or in vitro 
because of its infection ability. Compared with the DNA plasmid transfection, virus 
infection is less toxic to the cells and the time of gene expression is more flexible 
based on virus types. Among all the viral vectors, lentivirus has its unique advantage 
of integrating the transgene into the host genome so that the target protein can be 
expressed in the daughter cells. The 3
rd
 generation lentivirus packaging system has 
made the application of lentivirus safer than before as the viruses integrated in the 
cells are unable to proliferate by themselves. Therefore, we chose lentivirus to 
construct the viral vector for stably expressing AOX gene in mammalian cells. 
However, lentivirus infection also has disadvantages. The copy number of the target 
gene and the insertion site on the host genome are uncontrollable after infection. 
Different copy numbers causes that the expression level of target gene varies from cell 
to cell. And incorrect gene insertion can even lead to cell death.  
The U2OS cell line is a fast growing cancer cell line isolated from the human 
osteosarcoma. Mitochondrial morphology is maintained well in this cell line and 
clearly observed after immunostaining under microscope. Moreover, the MOI 
(multiplicity of infection) value for lentivirus and U2OS cell is low, which means 
U2OS cell can be easily infected by lentivirus. Thus we used the constructed AOX 
lentiviral vector to infect U2OS cell line for studying the AOX function in the 
mitochondria. According to the immunostaining result, only 30% of the cells showed 
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the presence of AOX protein, whereas the western blotting result showed high level of 
AOX compared with the reference protein SDHA, indicating that AOX could be 
over-expressed in the infected cells. As one of the mitochondrial membrane protein, 
the distribution of AOX reflected the morphology of mitochondria.  
The low efficiency of virus infection might depend on many factors. Since virus 
invading is harmful to the cell, the non-infected cells gain advantages of cell growth 
and generally take up the majority of cell population. The exogenous gene would 
inhibit cell division or stimulate cell apoptosis if they were inserted into critical locus 
of the host genome. Additionally, the exogenous gene itself can be disadvantageous to 
the cell. Unfortunately, the AOX lentiviral vector contained no selective marker for 
screening infected cells. Therefore, we could not isolate positive clones and 
specifically amplify them in selective medium.  
In addition to AOX, the EGFP gene was also expressed by the lentiviral vector in 
U2OS cells. The green fluorescence protein (GFP) encoded by EGFP is a popular 
marker to track the expression of target gene as the GFP is easily observed under 
fluorescent microscope. Since AOX protein was only visualized after binding to the 
fluorescent antibody, GFP could preliminarily indicate whether the gene cassette 
carried by lentivirus was successfully integrated into the cell. Theoretically, the AOX 
and EGFP genes should be expressed at the same level in each cell. However, the 
immunostaining images demonstrated the opposite result, revealing that the 
expression level of EGFP was quite uneven in the U2OS cell population compared 
with AOX. The reason might lie in the IRES site that connected AOX and EGFP gene 
in the plasmid cassette. The IRES site is the RNA sequence that allows the ribosome 
to bind the internal sequence and initiate the translation via a cap-independent 
mechanism (Pelletier and Sonenberg, 1988). With this site, co-expression of two 
independent genes can be driven by a single promoter. However, the second gene 
translated by IRES site has been reported to have lower expression than the first gene 
in a bicistronic vector (Mizuguchi et al., 2000). This difference should have been 
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considered before constructing the vector, as long as we expected the same expression 
level of reporter gene and target gene. Although the expression of GFP was unstable 
in the infected cells, a cell containing GFP should express AOX as well. A flow 
cytometer could be used to select AOX positive cells based on fluorescent signals. But 
due to limitation of time and equipment, we gave up positive cell isolation. 
4.3. AOX function and application in the neurodegenerative 
disease model in vitro 
Some traditional functions of AOX have already been verified in the brain tissue and 
neuro-glia cells of newborn transgenic mice, including the antimycin A resistance and 
oxygen consumption ability in mitochondria. But how does AOX function under 
disease condition? Can AOX alleviate symptoms triggered by mitochondrial defects? 
Since the expression of AOX in the adult mice is low, will it be induced by the stress 
of diseases? These are the main questions in regard to the feasibility of AOX 
application in neurodegenerative diseases. And the purpose of lentiviral vector 
construction is to answer the questions by introducing AOX into disease models.  
We established an in vitro disease model to mimic the SCA28 disease. SCA28 is a 
representative neurodegenerative disease that shows defects of mitochondrial 
respiratory chain and fragmentation of mitochondrial network. This disease is caused 
by mutations in the AFG3L2 gene that encodes a mitochondrial protease (Di Bella et 
al., 2010). It is known that AOX can compensate the blocked mitochondrial 
respiratory chain and reduce ROS production, but whether it can regulate or interact 
with mitochondrial quality control proteins such as AFG3L2 has not been proved. To 
test the AOX function in this in vitro disease model, we first infected U2OS cells with 
AOX lentivirus. When the GFP signal was observed in the cells, we knocked down 
the AFG3L2 gene of these cells by siRNA double transfection. No band of AFG3L2 
protein was detected on western blots after the double transfection. As AFG3L2 gene 
regulates the processing of OPA1, an important protein for mitochondrial fusion, 
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AFG3L2 gene silencing can cause L-OPA1 cleavage and mitochondrial fragmentation. 
Therefore, we evaluated the AOX function by comparing these two results in WT 
cells and AOX lentivirus infected cells before and after AFG3L2 silencing. To 
eliminate the impact of transfection on the cells, the samples also included cells 
transfected with scrambled siRNA as negative control. But no difference was found 
between untreated cells and the negative control.  
OPA1 is not only responsible for mitochondrial fusion, it also interacts with complex I, 
II and III of the mitochondrial respiratory chain, stimulates electron transportation and 
prevents proton leakage (Duvezincaubet et al., 2006; Lenaers et al., 2009). In addition, 
OPA1 can resist cell apoptosis via cristae remodeling (Olichon et al., 2003; Cipolat et 
al., 2006) Based on the western blot of OPA1, L-OPA1 was lost after AFG3L2 gene 
knock down, both in WT cells and AOX cells. The complete transition of L-OPA1 to 
S-OPA1 might result from inhibition of mitochondrial respiration or induction of cell 
apoptosis. Although AOX seems not to prevent the degradation of L-OPA1, several 
reasons can explain this result. First, compared with various stresses that the cells 
suffered from both the process of virus infection and siRNA transfection, the effect 
brought by AOX might be too small to alleviate the OPA1 destabilization caused by 
these stresses as well as AFG3L2 knock down. Second, the impact of AOX might not 
be as significant as AFG3L2 on the regulation of OPA1 processing. More extremely, 
AOX might not even play a role in rescuing OPA1 degradation at all. Therefore, AOX 
failed to maintain the normal pattern of OPA1 after AFG3L2 silencing. Despite of all 
the possible reasons, a conclusion was still too early to be drawn unless more repeated 
experiments were carried out to verify this result. Even though AOX can not prevent 
OPA1 destabilization, it may still rescue the defective cells from other aspects.  
Abnormal mitochondrial morphology has been commonly found in neurodegenerative 
diseases (Knott and Bossy-Wetzel, 2008; Chen and Chan, 2009; Su et al., 2010). 
Mitochondria in the respiratory active cells normally form a fusion network to 
exchange metabolites and mtDNA, whereas in resting or damaged cells mitochondria 
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are represented as fragmented structures (Westermann, 2012). It has been reported 
that mitochondrial fragmentation caused by dysfunction of mitochondrial protein 
synthesis, is a key reason for AFG3L2-related neurodegeneration (Almajan et al., 
2012). Therefore, it would be interesting to see whether AOX could protect the 
mitochondria in the disease model by recovering the balance of mitochondrial 
dynamics. In normal condition, mitochondria were fused with each other and together 
constructed a tubular network. However, when AFG3L2 gene was knocked down, this 
network was disrupted and lead to fragmented mitochondria. According to our 
statistical result, less fragmented mitochondria were shown in the cells infected by 
AOX lentivirus than WT cells after AFG3L2 siRNA transfection, which suggested 
that AOX might be beneficial to balance the mitochondrial dynamics. This is a very 
interesting finding. As discussed previously, the OPA1 cleavage pattern was not 
changed in the presence of AOX, meaning that AOX might not rescue the OPA1 
destabilization caused by AFG3L2 defects. However, the most significant result 
brought by OPA1 degradation—the mitochondrial fragmentation—was alleviated by 
AOX regardless of OPA1 rescue, contradicting to the common belief that OPA1 
cleavage is the essential reason for mitochondrial fragmentation based on AFG3L2 
dysfunction. According to revealed functions of AOX, this alleviation may due to 
reduced oxidative stress, compensated electron transport chain, improved metabolic 
and signaling homeostasis (Vanlerberghe, 2013), or decreased susceptibility to 
programmed cell death (Li and Xing, 2010). More boldly assuming, AOX might even 
affect other mitochondrial fusion or fission proteins through unknown mechanisms or 
regulate pathways that are important for protecting the mitochondrial network. 
Among all the potential elements, the relationship between mitochondrial respiration 
and mitochondrial membrane dynamics is of great significance to explore, as AOX is 
especially active for maintaining mitochondrial respiratory chain. The significant 
reasons leading to mitochondrial fragmentation besides OPA1 cleavage probably 
include respiratory defects. Although it is hard to determine which factor brought by 
AOX mainly prevents the mitochondrial fragmentation without further identification, 
this result indicates a new perspective for studying mitochondrial dynamics and for 
 58 
seeking potential therapy to treat mitochondrial diseases.   
To be more objective, many conditions should be considered to evaluate the reliability 
of this result. First, the sample size of AOX cells was much smaller than WT cells. 
Because the infection efficiency of AOX lentivirus varied between different batches 
of cells and was relatively low overall. Difficulties arose when looking for positive 
cells with EGFP fluorescence. Second, the resolution of images was not ideal with the 
fluorescence microscope, further decreasing the number of cells with distinguishable 
mitochondrial morphology. Third, the manual scoring method might lead to bias for 
classifying different mitochondrial morphology, since many cells were neither 
completely tubular nor fragmented but looked like a shape in between. Fourth, both 
processes of virus infection and siRNA transfection triggered stress to the cells. Thus, 
the effect of AOX might not only target at rescuing the defects caused by loss of 
AFG3L2 but might also alleviate other cell damages during the process. Fifth, 
although the western blot showed that AFG3L2 protein were absent in the transfected 
cells overall, we could not confirm AFG3L2 was knocked down in every single cell 
selected for quantifying the mitochondrial fragmentation, which might cause 
controversial result of the quantification. Unfortunately, the whole process of this 
experiment took more than 10 days, hence we have no time to repeat it more times 
and collect more data.  
Considering all the drawbacks, there are definitely improvements that we can make 
for the future experiments. Most importantly, a selective marker in the viral vector is 
necessary for the cell screening as the infection efficiency is relatively low. If we 
could selectively clone the positive cells which expressed AOX, the time of 
establishing the AFG3L2 knock down cell model would be shorter and cells could 
recover from the virus infection before transfection. Secondly, since siRNA 
transfection can only silence the AFG3L2 gene transiently, the shRNA transfection 
may be used to knock down the target gene for longer time and is better for further 
functional analysis. Thirdly, the quantification method of mitochondrial morphology 
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should avoid bias. Some innovative quantitative analysis of mitochondrial 
morphology have been developed to replace simple manual quantification, including 
high-content imaging based on machine learning (Leonard et al., 2015), 
super-resolution imaging coupled with membrane potential analysis (Jakob et al., 
2015), and quantification using multiple parameters (Wiemerslage and Lee, 2016). 
Besides, we may also find new plugins for mitochondrial morphology analysis on 
ImageJ software.  
In addition, the U2OS cell model might not be the best for miniaturizing the 
mitochondrial morphology in neurodegenerative diseases. Because neurons behave 
differently from the actively dividing U2OS cells. And mitochondria play a more 
important role in neurons than other type of cells on the aspects of energy supply and 
transmission as well as membrane potential maintenance (Knott et al., 2008). 
Mitochondrial fragmentation may bring more significant and chronic effects on 
neurons under disease condition. Some neuroblastoma cells or neural cells 
differentiated from induced pluripotent stem cells (iPSC) would be more suitable cell 
models for studying mitochondrial dynamics in neurodegenerative diseases. 
Nevertheless, the U2OS cells model still provides important implications about 
mitochondrial fragmentation caused by AFG3L2 defects. The fragmentation 
phenotype not only results from OPA1 mediated fragmentation, but might also relate 
to respiratory defects. Counteracting these defects could also rescue the 
morphological changes of mitochondria, regardless of OPA1 degradation. This 
finding should be verified by more elaborate experiments with different cell types and 
quantitative methods, which would develop our understanding of the relationship 
between mitochondrial dynamics and mitochondrial respiration, giving rise to new 
ways of treating mitochondrial diseases. 
Molecular basis of AOX has been widely studied in different plants both in vitro and 
in vivo, while its application in mammalian system is much more limited. The 
applications of AOX in engineered human cells and transgenic mice have implied a 
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way of rescuing the defective mitochondrial respiratory chain, mitigating the 
oxidative stress in the cell and curing mitochondrial diseases (Hakkaart et al., 2006; 
Dassa et al., 2009; El-Khoury et al., 2013). Based on these achievements, we tested 
the function and activity of AOX in the mouse brain and neuro-glia cells for the first 
time and generated a lentiviral vector for applying AOX in more mammalian cell 
types and tissues. The most exciting finding is that the AOX lentivirus significantly 
rescued the degree of mitochondrial fragmentation in the U2OS disease model cells 
established by AFG3L2 gene silencing. Our study proposes an inspiring hint of 
applying AOX in future research or therapy of neurodegenerative diseases, especially 
those involve abnormal mitochondrial morphology. We also appeal that more 
functional studies about AOX should be done for the mammalian system. Because 
AOX is not only a promising candidate for developing efficient therapies but also a 
good tool for studying pathological mechanism of neurodegenerative diseases. 
5. Conclusion 
As the aim of this study has indicated, neurodegenerative diseases that are associated 
with mitochondrial dysfunction, have increasing impacts on human health and life 
currently. We propose a new way to treat these diseases with the alternative oxidase 
(AOX), which is proved in various studies to maintain the function of damaged 
mitochondrial respiratory chain and reduce the ROS production. 
Since Ciona intestinalis AOX gene is absent in mammals, an engineered mouse model 
has been generated to express AOX all over the animal, with one copy of Ciona AOX 
gene inserted into the Rosa26 locus of C57Bl/6J mouse genome. Hemizygous 
AOXRosa26 transgenic mice were selected as the research materials. Our study first 
investigated the expression and function of AOX in the brain of this transgenic mouse 
model, finding that the amount and activity of AOX protein in the brain decreased 
along with age. In addition, we established a lentivirus vector to apply AOX gene to 
human cells, testing the therapeutic function of AOX in a neurodegenerative disease 
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model in vitro. And we observed that the fragmented mitochondrial phenotype of the 
AFG3L2 silencing disease model was alleviated by AOX despite of OPA1 cleavage, 
indicating that this mitochondrial phenotype is not only due to OPA1 cleavage, but 
also related to respiratory defects. This sheds a light on novel aspects that could help 
rescue mitochondrial morphological changes and implies the promising application of 
AOX in treating neurodegenerative diseases. 
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